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Immune-mediated neuropathies cause inflammation of the peripheral nerve, with 
disruption of the axon, myelin sheath or both. In the acute setting, immune-mediated 
neuropathy can lead to respiratory muscle weakness, in the group of Guillain-Barré 
syndrome (GBS). In the chronic setting, immune-mediated neuropathies, which can 
be sensorimotor (CIDP, MADSAM), sensory predominant (anti-MAG neuropathy, 
others) and purely motor (MMN), cause permanent and progressive disability and 
impairment in activities of daily living.  
Anti-gangliosides antibodies have been detected with varying frequencies in the 
immune-mediated neuropathies, with the highest prevalence being anti-GQ1b 
antibodies in Miller-Fisher syndrome and anti-GM1 antibodies in MMN and AMAN 
(axonal variant of GBS). There is evidence that the inflammatory potential of these 
antibodies is reliant upon complement activation, and the resultant formation of the 
MAC (membrane attack complex).  In experimental models of anti-ganglioside 
mediated neuropathy, inhibition of the complement cascade results in the complete 
prevention of inflammatory damage, and preserved nerve function.  
Multifocal motor neuropathy is a chronic, progressive purely motor neuropathy which 
causes weakness and wasting. IgM anti-GM1 antibodies are found in between 50 – 
80% of affected cases. The only current treatment for MMN is high dose IVIg 
(intravenous immunoglobulin). The response rate to IVIg is around 80%, and cases 
who are antibody negative can also respond to this treatment. However, the effect is 
temporary, and further doses are usually re-administered at around 4 weekly 
intervals. Since it is a human blood product which is pooled from donated blood 
products, it is in short supply and does carry some important side effects. 
The main focus of this study was to test a novel therapy for immune-mediated 
neuropathy. The treatment tested was the first complement inhibitor licensed for 
human use, eculizumab. In this study it has been tested in the treatment of MMN, in 
patients who may also be receiving treatment with IVIg. The aim was to collect safety 
information regarding the concurrent use of these biological products, and to test for 
any neutralising effect between them. Any beneficial effect of complement inhibition in MMN was investigated by various outcome measures, clinical, functional and 
electrophysiological.  
The results of the clinical trial showed that eculizumab treatment was associated with 
a higher rate of adverse events, in patients who were or were not receiving IVIg. Most 
adverse events were mild to moderate in severity, none were unexpected, and more 
occurred during the induction phase of treatment than during the maintenance phase. 
The most common adverse event was headache, which 69% of patients experienced 
at any time. Two thirds of all headaches occurred in the induction phase. IVIg did 
lower the serum concentration of eculizumab, however eculizumab activity was not 
compromised.  
There were significant changes to subjective scores overall, and some objective 
scores also displayed significant improvement. However repeated IVIg doses were 
still required by those who were regularly using it prior to the study, albeit perhaps at 
slightly longer intervals. Electrophysiology showed small significant improvement in 
two parameters in keeping with improved nerve conduction.  Overall it was felt that 
complement inhibition was associated with some potential benefits in MMN however 
did not substitute the therapeutic mechanism of action of IVIg. Aspects of the study 
design meant that evidence of efficacy could not be concluded from this study, and 
further trials are necessary to elucidate this.  
In addition, this thesis presents a laboratory-based study in which further information 
about the binding characteristics of the IgM GM1 antibody were sought using different 
methods than the standard ELISA technique. Using a combinatorial glycolipid 
microarray, MMN sera were screened against a large range of glycolipid pairs, to test 
for novel epitopes in the ‘antibody negative’ MMN patients without anti-GM1 antibody. 
It was found that in patients who did not have an antibody to GM1 or any other single 
ganglioside on ELISA or microarray, there was presence of an antibody to the 
glycolipid pair, GM1:GalC. It was shown that the IgM GM1 antibody in MMN is also 
inhibited from binding to GM1 in a solid phase and live membrane due to the local 
presence of GD1a. These findings lead to greater understanding of the pathogenesis 
of MMN and possibility of a more sensitive diagnostic test.  Table of contents 
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Chapter 1.  Introduction 
1.1  Overview of peripheral nervous system 
1.1.1  Peripheral nerve structure and function 
The peripheral nerves control motor, sensory and autonomic functions of muscles 
and organs, relaying afferent and efferent information from the brain to the rest of 
the body, such as the stimulus for muscle contraction or sensation of pain. The 
peripheral nerves comprise 12 cranial nerves and 31 spinal nerves in pairs. Each 
nerve is composed of bundles of nerve fibres, which themselves comprise 
multiple axons lying adjacent to each other. The cell bodies of these axons reside 
in the ganglia, within the gray matter of the spinal cord (or the brain stem for 
cranial nerves). The dorsal root ganglion contains the cell bodies of sensory 
nerves; the anterior horn cell at the ventral root contains the cell bodies of the 
motor nerves.  
With the exception of small (less than 1µm diameter) fibres, all peripheral nerves 
are myelinated. Myelin is produced by the Schwann cells, a type of glial cell 
which exists in the endoneurium of the peripheral nerves. Myelin is composed of 
around 80% protein and 20% lipid, a large amounts of which are glycosylated, 
that is, they bear sugar moieties on their surface.  The major function of myelin is 
to insulate axons, allowing faster conduction of nerve impulses. At the distal end 
of the nerve fibre is the interface with the effector tissue. For motor nerves this is 
called the motor end plate, or the nerve terminal. Here the axons emerge from 
the myelin-encasing and communicate with the muscle unit by release of 
neurotransmitter.  Each axon stimulates one motor unit within a muscle, and 
parallel axon firing results in summation of individual motor units contracting 
simultaneously and thus results in muscle contraction  (Shin J.Oh,2003a).  
1.1.2  Blood-nerve barrier 
The function of the blood-nerve barrier, similarly to the blood brain barrier, is to 
protect excitable neural tissue from potentially toxic substances in the circulation, 
and maintenance of the ionic homeostasis the endoneural space.  It is formed by 8 
 
the specialised endothelium of blood vessels which pass through peripheral 
nerves, lined by cells that are non-fenestrated, sealed by tight junctions, lined by 
a basement lamina and coated with negatively charged glycolipids that 
electrostatically repel many proteins  (Kiernan,1996).  
1.1.3  Electrophysiology 
Nerve impulses, generated in the cell body, are propagated distally by conduction 
of action potentials along the axonal membrane, by the depolarisation of the cell 
membrane, which is driven by movement of sodium and potassium ions. The role 
of the myelin sheath is to accelerate the journey of electrical charge, by insulating 
the axon and therefore preventing the repolarisation while the impulse travels its 
length. There are gaps between the myelinated nerve segments at intervals 
along the axon, known as the nodes of Ranvier, and at these non-myelinated 
points the axon then can repolarise. In this way, the nerve impulse jumps from 
node to node, known as ‘saltatory’ conduction  (Shin J.Oh,2003a).  
Nerve conduction and muscle contraction properties are studied in the field of 
electrophysiology, and the techniques employed are essential tools for the clinical 
and experimental study of peripheral nerve disease.  
1.1.3.1  Nerve conduction studies (NCS) 
An electrode is applied to the skin at a known anatomical location of a peripheral 
nerve route, for example the median nerve at the wrist. A sensor is applied to the 
muscle supplied by that nerve, in the example of the median nerve (Figure 1.1) 
that muscle would be the abductor pollicis brevis (APB), and measures the 
compound muscle action potential (CMAP) voltage (mV) which results from the 
nerve impulse applied. The distal motor latency (DML) is the time taken for 
impulse to travel from the distal stimulation point (wrist) to the muscle (APB). By 
stimulating this same muscle from two separate anatomical points along the 
nerve (wrist and elbow), the conduction velocity of the nerve segment between 
those two points can be calculated  (Shin J.Oh,2003b).  9 
 
To measure nerve conduction velocity of the proximal, and thus inaccessible to 
testing, nerve segments, the late response, or F-wave, is calculated. Using 
supramaximal stimulation of the distal nerve segment, the F-wave latency 
records the time for the impulse to travel from the point of stimulation, proximally 
to reach the spinal nerve root, and a small reflection of the impulse to travel 
distally back to the motor end plate. From this the velocity of conduction from the 
point of stimulation to the spinal cord can be derived  (Shin J.Oh,2003b).  
The main objective of nerve conduction studies is to 1) identify the anatomical 
pattern of nerve dysfunction and 2) differentiate between axonal and 
demyelinating pathology. NCS features of axonal neuropathy are reduced or 
absent distal CMAPs, with normal conduction velocity and distal motor latencies. 
On the contrary, demyelinating neuropathies cause delayed conduction, with 
prolonged DML, slowed conduction velocities, and prolonged F-wave latencies  
(Hughes,2002) .  
1.1.3.2  Electromyography (EMG) 
Using a needle electrode inserted into the muscle belly, muscle activity is 
recording during at rest and during active contraction against resistance. In the 
resting phase, any spontaneous (abnormal) activity can be recorded, such as 
fibrillation, which is a signal of ongoing denervation. In the contraction phase, the 
motor unit activity can be visualised (and heard) as an interference pattern, 
comprising characteristic waveforms for each motor unit, repeated with 
increasing frequency as the force of contraction increases  (Shin J.Oh,2003b).   
1.1.4  Classification of peripheral neuropathy 
The term neuropathy is generally understood to mean peripheral neuropathy, in 
which there is disruption of the peripheral nervous system. The clinical features 
depend on the anatomical and functional distribution of the disruption, and 
include motor symptoms (weakness, muscle wasting), sensory symptoms 
(numbness, pain, paraesthesia) and autonomic symptoms (nausea, postural 
hypotension and urinary retention). The population prevalence of neuropathy is 10 
 
about 2400 per 100 000 (2.4%), rising with age to 8000 per 100 000 (8%)  
(Martyn et al.,1997). 
Conditions affecting the peripheral nerves can be classified by different features  
(Poncelet,1998) 
1)  Type of nerve involved: purely motor, purely sensory, sensorimotor, or 
autonomic.  
2)  Sites of nerve damage: proximal, distal, symmetrical, multifocal, 
mononeuropathy, and polyneuropathy 
3)  Aetiology: toxic, infective, autoimmune, diabetic, paraneoplastic, 
nutritional, mechanical, hereditary.  
The most common neuropathy in the developed world is diabetic neuropathy, 
which tends to be a distal symmetrical sensory polyneuropathy  (Llewelyn,1995). 
Autonomic and cranial (third nerve palsy) neuropathies are also encountered in 
diabetes.  In developing countries, infective causes are prevalent, mostly related 
to HIV infection (and the medications used to treat HIV), causing a painful distal 
sensorimotor polyneuropathy  (Gonzalez-Duarte et al.,2008). Neuropathy caused 
by Mycobacterium leprae (leprosy) remains the most common treatable 
neuropathy in the world, although its prevalence is declining worldwide, the 
number of new cases worldwide in 2006 was 250,000, mainly found in areas of 
extreme poverty  (Scollard et al.,2006).  
1.2   Immune-mediated neuropathy 
Immune-mediated neuropathies are characterised by inflammatory pathology, 
and have an immune-related pathogenesis.  Immune-mediated neuropathies can 
first be divided into acute and chronic.  
Acute immune-mediated neuropathy is better known as the Guillain-Barré 
syndrome (GBS), and is characterised by acute onset symmetrical limb 
weakness and sensory change, which reaches a nadir within less than 4 weeks  
(Hadden et al.,1998). Typically, the weakness is ascending, however in the Miller 11 
 
Fisher variant this is typically descending. The two main disease groups in GBS 
are AIDP (acute inflammatory demyelinating polyradiculoneuropathy) and AMAN 
(acute motor axonal neuropathy).  The overall incidence of GBS worldwide is 
rare, at around 1.5/100,000 per year (Alshekhlee et al.,2008), however it is the 
leading cause of neuromuscular paralysis and is potentially life threatening 
(mortality 2-3%). Although GBS is self remitting, the average recovery to walking 
unaided time without treatment is 100 days, and 20% of cases (despite 
treatment) are left with permanent disability at 2 years  (Rees et al.,1998), or can 
progress to a chronic form.  
In the chronic immune-mediated neuropathy group, there are CIDP (chronic 
inflammatory demyelinating polyradiculoneuropathy), MMN (multifocal motor 
neuropathy), MADSAM (multifocal acquired demyelinating sensory and motor 
neuropathy), anti-MAG neuropathy and paraproteinaemic neuropathies.  
CIDP is a sensorimotor polyneuropathy which reaches it nadir in more than 8 
weeks, and includes progressive and relapsing phenotypes. The prevalence is 3-
4/100,000 with equal numbers of men and women affected. Unlike GBS, 
respiratory muscle weakness is uncommon. Electrophysiology shows widespread 
features of demyelination. First line treatment in CIDP remains corticosteroids, 
and between 65 – 95% of patients respond favourably to steroids. Other 
treatment options are IVIg (intravenous immunoglobulin) and plasma exchange, 
which all show similar efficaciousness to corticosteroids  (van Schaik et al.,2002).  
MADSAM, originally known as Lewis-Sumner syndrome, is thought to be a 
variant of CIDP, and is similar to MMN due to the presence of conduction block in 
motor nerves. However, in MADSAM there are also significant sensory 
abnormalities (Verschueren et al.,2005).  
Anti-MAG neuropathy is characterised by a slowly progressive sensory 
neuropathy, with an upper limb tremor and unsteadiness of gait. It is usually 
associated with IgM paraprotein directed against myelin-associated glycoprotein 
(MAG). Treatment with IVIg, plasma exchange and corticosteroids have not 12 
 
shown great benefit, however recently rituximab has shown significant short and 
long-term benefit  (Dalakas,2010). 
1.3  Multifocal Motor Neuropathy  
1.3.1  History 
It is impossible to explain the background to MMN without introducing the 
concept of conduction block. The phenomenon, of inability of nerve impulse 
propagation beyond a certain point in the nerve, has been described in nerves 
following trauma since around 1860, and experimentally reproduced (using 
tourniquets) since 1944, following which electrophysiology of conduction block 
was investigated  (Trojaborg,1978). It was initially thought that conduction block 
was a reversible lesion which resolved in less than 2 months, however later 
studies described conduction block lasting months following trauma  
(Harrison,1976; Trojaborg,1977), and at common compression points, in the 
condition now known as ‘hereditary neuropathy with liability to pressure palsies’ 
(HNLPP)  (Magistris et al.,1985).  
In succession, came the discovery of conduction block in motor nerves of 
patients who were thought to have a lower motor neuron variant of motor 
neurone disease (MND)  (Roth et al.,1986).  Various neurologists in the late 
1980’s described similar findings, where conduction block of motor, but not 
sensory nerves, was found in patients presenting with asymmetrical, 
predominantly upper limb weakness and wasting, and absence of sensory 
symptoms  (Parry et al.,1988).  Initially it was presumed that this was a motor-
predominant variant of CIDP, but when treatment with high dose corticosteroids, 
known to improve CIDP, failed to show benefit in this motor-variant, it was 
suspected that this disease was in fact a separate entity  (Pestronk et al.,1988).  
In addition, immunological testing of patients with this condition showed that IgM 
antibodies against GM1 and other gangliosides existed in the majority of cases 
(50 – 80%). Since then hundreds of cases of MMN have been described, 
however it remains rare, with an estimated prevalence of between 1 to 2 per 
100,000 population.  13 
 
1.3.2  Clinical features 
Multifocal motor neuropathy (MMN) is distinct from other chronic immune-
mediated neuropathies, due to its characteristic clinical and electrophysiological 
features. Distal motor nerve paralysis usually involves the upper limbs initially, 
with a stepwise, asymmetric progression to involve motor nerves at other sites. 
Muscle atrophy occurs later in the course of the condition and usually involves 
distal small muscles first (Biessels et al.,1997; Bouche et al.,1995; Krarup et 
al.,1990). Sensory nerves are rarely affected although some patients may have 
minor sensory symptoms  (Krarup et al.,1990). Conduction block across a motor 
nerve segment is the electrophysiological hallmark, and essential criterion for 
diagnosis  (Bouche et al.,1995; van Schaik et al.,2006).   
1.3.3  Electrodiagnostic criteria 
As described in the previous section, nerve conduction studies are used to 
measure the velocity of nerve impulses, and the magnitude of effector response 
in the muscles innervated by motor nerves. Figure 1.1 demonstrates the 
electrophysiological phenomenon of conduction block, where stimulation of the 
median nerve at the wrist results in a CMAP in the APB muscle of the hand, 
however when the median nerve is stimulated more proximally, no CMAP is 
detected in the APB muscle. This means that between the stimulation points at 
the wrist and the elbow, conduction block exists, and in the case illustrated, this 
appears to be an almost 100% diminution. The degree of conduction block is 
expressed as the % CMAP amplitude (or area) reduction, calculated by ((distal 
CMAP – proximal CMAP/distal CMAP) x 100%).   
 14 
 
 
Figure 1.1 Motor nerve conduction study showing conduction block in the 
right median nerve (left panel), and a schematic drawing (right) showing 
the anatomical origin of this. Nerve stimulation at the anatomical locations 
of the median nerve 1) wrist 2) elbow and 3) axilla, and the corresponding 
CMAP recorded from the abductor pollicis brevis muscle in the hand. The 
CMAP amplitude is reduced to almost zero when the nerve is stimulated at 
the elbow, showing that conduction block occurred in the median nerve 
between the wrist and the elbow. The CMAP recorded from stimulation at 
the axilla is temporally dispersed and therefore no statement regarding 
conduction block can be made about this nerve segment, although this 
dispersion in itself may represent demyelination in this nerve segment.  
 
American  (Olney et al.,2003) and European  (van Schaik et al.,2006) consensus 
criteria exist for the diagnosis of MMN, and the electrodiagnostic criteria differ 
slightly in the definition of ‘probable’ conduction block, but are otherwise similar. 
Figure 1.2 presents the electrodiagnostic criteria of the European Federation of 
Neurological Societies (EFNS), originally released in 2006.  In nerves where 
there is significant temporal dispersion, there can be the mistaken appearance of 
conduction block due to interphase cancellation, and therefore at the most 
‘probable’ CB can be diagnosed from such a nerve.  15 
 
 
Figure 1.2. Electrodiagnostic criteria in MMN, adapted from European 
Federation of Neurological Societies/Peripheral Nerve Society guideline on 
management of multifocal motor neuropathy, 2006  (van Schaik et 
al.,2006) . 
 
There is some current debate about threshold for diagnosis of CB, as there are 
some case reports of patients in whom clinical evidence of MMN was not 
accompanied by conduction block adequate to qualify for probable CB, until later 
years when the disease progressed, and thus treatment has been delayed  
(Ghosh et al.,2005).  In addition, there are cases where MMN is so advanced at 
presentation, that conduction block may be imperceptible, due to the degree of 
axonal degeneration, such that there is no appreciable difference between 
proximal and distal CMAP.  
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1.3.4  Pathology  
The pathology of MMN is still largely unknown, and further work is being carried 
out to elucidate the pathophysiology.  However, it has been classed as an 
immune-mediated neuropathy, and thought to be antibody mediated, mainly due 
to the clinical response in MMN to immune-modulating therapy with high dose 
immunoglobulins, the discovery of anti-GM1 antibodies in the majority of cases, 
and the evidence (explained further in this text) that anti-GM1 antibodies can 
cause conduction block in experimental models.  
Multifocal motor neuropathy has originally been thought of as a demyelinating 
disorder, due to the initial pathological studies which showed demyelination at 
sites of conduction block.  However, many studies have shown that axonal 
degeneration is an important feature, and is an independent predictor of 
weakness  (Van Asseldonk et al.,2006). Until recently, no convincing 
histopathological studies existed in MMN, as nerves had been sampled outside 
the area of conduction block, and were relatively normal. However, Taylor et al 
performed nerve biopsy in 8 patients with MMN using intraoperative nerve 
conduction studies to localise the site of CB  (Taylor et al.,2004). The 
predominant abnormality found was multifocal axonal degeneration. There was 
also some minor evidence of remyelination, however no overt features of 
demyelination. This is a surprising finding given that that conduction block is 
thought to be a feature of demyelination. Further pathophysiological studies are 
required. 
1.3.5  Treatment of MMN 
The finding of anti-ganglioside antibodies in MMN led to trials using immune 
modulating treatments. Intravenous immunoglobulin (IVIg) is pooled IgG 
extracted from the plasma of over one thousand blood donors. It is the gold-
standard of treatment of MMN, and has been shown to cause significant muscle 
strength improvement in up to 80% of patients  (Azulay et al.,1994; Leger et 
al.,2001; Van den Berg et al.,1995). However, its effects are short-lived and 
maintenance treatment is required. Maintenance regimes are individually tailored, 17 
 
with most patients requiring cyclical dosing at 3-4 weekly intervals. Despite long 
term therapy, disease progresses over time causing worsening disability  
(Terenghi et al.,2004). All immunomodulating therapies were evaluated in a 
recent Cochrane review  (Umapathi et al.,2009). Corticosteroids and plasma 
exchange are ineffective in MMN  (Lehmann et al.,2008; Van den Berg et 
al.,1997), and trials of various immunomodulatory therapies, including rituximab, 
mycophenolate and interferon-gamma, have not shown sufficient benefit to allow 
adoption in clinical practice. In some cases, corticosteroids have been shown to 
cause drastic worsening of weakness  (Donaghy et al.,1994) and are therefore 
avoided in MMN.  
 
1.3.6  Anti-ganglioside antibodies in MMN 
Anti-ganglioside antibodies are widely thought to be responsible for the 
pathogenesis in MMN, and IgM antibodies to GM1 ganglioside in particular are 
found in between 50 – 80% of cohorts published.  The finding of anti-GM1 
antibody is supportive for the diagnosis, but its absence does not rule out the 
disease. 
The discovery of anti-GM1 antibody in MMN came parallel with the discovery 
anti-ganglioside antibodies in other autoimmune neuropathies, and accumulating 
evidence for their pathogenicity.  
 
1.4     Anti-ganglioside antibodies in the pathogenesis of  immune-mediated 
neuropathy 
1.4.1  Gangliosides 
Gangliosides are glycosylated lipids, with a ceramide (lipid) backbone attached to 
an oligosaccharide of varying structure, to which are attached sialic acid 
residues. The family of gangliosides are named according to the Svennerholm 
short-hand nomenclature system, in which M, D, T and Q refer to the number of 18 
 
sialic acid residues i.e. mono-, di-, tri- and tetrasialogangliosides, respectively, 
and the numbers 1, 2, 3 refer to the order of migration of the gangliosides on thin-
layer chromatography. Figure 1.3 shows the basic structure of the most common 
gangliosides in the human nervous system. More than 100 different gangliosides 
have been characterised within vertebrates alone.  Gangliosides are known to be 
abundant in the central and peripheral nervous system, where their main role is in 
cell signalling and adhesion, through which they regulate neural development and 
regeneration.  
 
Figure 1.3. Basic structure of major neural gangliosides. NeuAc is sialic 
acid, GalNAc is N-acetylgalactosamine.  
 
1.4.2  Anti-ganglioside antibodies in neuropathy 
Anti-ganglioside antibodies are most firmly linked to pathogenesis of neuropathy 
in the Miller-Fisher syndrome (MFS), an acute, self-remitting variant of Guillain-
Barré syndrome which manifests with acute onset of ophthalmoplegia, ataxia, 
and areflexia, and results in a descending paralysis  (FISHER,1956). Anti-GQ1b 
antibodies are detected in upwards of 90% of cases of this condition  (Willison et 
al.,1993), with complete absence of anti‐GQ1b IgG antibodies from normal and 
other disease control groups, indicating a high level of specificity for this disease. 
Additional evidence of this antibody as the pathogenic mediator is that antibody 
titres peak at clinical presentation, and decay rapidly with the course of clinical 
recovery  (Mizoguchi,1998). Also, ophthalmic nerves are known to be rich in 
GQ1b ganglioside (Chiba et al.,1997).  19 
 
Further evidence of antiganglioside antibodies in neuropathy comes from the 
association between AMAN variant of Guillain-Barré syndrome and IgG 
antibodies to GM1, and GD1a; which are shown to exist preferentially in this 
variant rather than AIDP  (Ho et al.,1999; Kuwabara et al.,1998).  In cohorts of 
Guillain-Barré syndrome, the presence of IgG anti-GM1 antibodies is strongly 
correlated with axonal versus demyelinating neuropathy, predominant motor 
involvement, more severe weakness and previous infection with Campylobacter 
jejuni.  The association with C. jejuni infection led to the theory of ‘molecular 
mimicry’  (Yuki et al.,2007), which there now exists substantial evidence 
regarding its major aetiological role in axonal variants of Guillain-Barré syndrome. 
‘Molecular mimicry’ describes the phenomenon where antibodies which develop 
during infection with C. jejuni, can cross-react with GM1 ganglioside, and 
therefore act as an autoantibody. The C. jejuni  and other gram-negative 
organisms, bear an external endotoxin, lipo-oligosaccharide (LOS), and these 
LOS have been shown to have ganglioside-like regions  (Godschalk et al.,2007).  
Other infections which are linked with GBS are Mycoplasma pneumoniae, 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), and more rarely influenzas  
(Jacobs et al.,1998). These organisms all bear carbohydrate structure on their 
surfaces which resemble peripheral nerve gangliosides  (Yu et al.,2006), and 
there are some associations between certain antecedent infections and certain 
autoantibodies, for example there is a correlation between CMV antibodies and 
GM2 antibodies in serum of patients with GBS  (Irie et al.,1996).  
1.4.3  Evidence of pathogenic potential of anti-ganglioside antibodies 
The pathogenic potential has been demonstrated in animal models for the major 
antibody-disease associations. Santoro et al showed this for anti-GM1 in 1996, 
by injecting the serum from a patient with MMN into rat sciatic nerve. The serum 
caused conduction block and pathological features of demyelination, in a 
complement dependent manner, where IgM and complement were localised to 
the nodes of Ranvier  (Santoro et al.,1992).  Rabbit models, inoculated with a 
bovine brain ganglioside mixture or isolated GM1, developed high anti-GM1 IgG 
antibody titres and acute flaccid paralysis  (Yuki et al.,2001).  Anti-GQ1b 20 
 
antibodies, in an in vitro murine model of neuropathy, caused complement-
mediated injury of peri-synaptic Schwann cells and caused disruption of pre-
synaptic motor nerve terminals at the neuromuscular junction  (Halstead et 
al.,2004).  Numerous other in vitro and in vivo studies demonstrate that anti-
ganglioside antibodies can mediate, in the presence of complement, impairment 
of nerve conduction and pathological changes of neuropathy  (Goodyear et 
al.,1999; Greenshields et al.,2009; O'Hanlon et al.,2003; Yuki et al.,2001). 
1.4.4  Complement system 
The complement system a key component of the innate immune system, and 
functions to aid antibodies in immune clearance of pathogens and promote 
inflammation  (Walport,2001).  It consists of over 30 proteins and pro-proteins, 
which are synthesised in the liver, and enzymatically activated in the serum in a 
sequential cascade-like manner.  
The cascade consists of three pathways that are initiated following recognition of 
different antigenic targets, the classical pathway recognises antibody-antigen 
complex, the alternative pathway recognises C3b binding to cell membranes, and 
the lectin binding pathway which recognises mannose-binding proteins (MBP) on 
microorganisms.   
The classical pathway begins with the activation of C1q via binding to the Fc 
region of the bound IgG (or IgM). This induces a conformational change in C1 
and the systematic activation of proteins occurs. C3 is cleaved to C3a and C3b, 
which themselves have important roles in innate defence: C3a triggers mast-cell 
degranulation, and C3b is a potent opsonising agent. The next important step, in 
which C3b is vital, is the formation of C5 convertase, which binds to and cleaves 
C5 to C5a and C5b.  From here the pathway is known as terminal complement, 
and comprised of proteins C5b – C9, which upon activation, assemble to form a 
pore-like structure, the membrane attack complex (MAC)  (Muller-
Eberhard,1985).  MAC inserts itself into the target cell membrane causing 
osmotic lysis, by the rapid influx of extracellular fluids, disruption of the ionic 21 
 
gradient across the membrane, rendering the cell or pathogen destructed  
(Janeway CA,2001). 
 
 
Figure 1.3. Complement cascade. A simplified schematic image of the 
complement cascade. Adapted from NIH Publication No. 03–5423, 
September 2003. 
Hereditary complement deficiencies are described for many of the complement 
factors, and result in an increased susceptibility to infections, in particular, from 
encapsulated bacteria. Bacteria which are protected by a polysaccharide 
capsule, including Neisseria meningitidis, Streptococcus pneumoniae, and 
Haemophilus influenza, must be lysed by MAC for their destruction. In the 
absence of terminal complement activation, increased susceptibility to infection 
with encapsulated bacteria is seen  (Figueroa et al.,1991).  22 
 
1.4.5  Complement as a therapeutic target in autoimmune neuropathy  
Complement fixation plays a major role in the antibody-mediated defence 
mechanism, via the classical pathway of complement activation, and has been 
shown to be active in many autoimmune diseases including renal, vascular, 
neurological disease.  
 With the knowledge that MAC could be detected in the target tissue of a variety 
of immune-mediated conditions such as polymyositis  (Morgan et al.,1984; 
Vanguri et al.,1988), research has been directed towards demonstrating the 
complement-fixing properties of the antibodies found in these conditions  (Latov 
et al.,1981). Much of the progress in this field has come from the study of 
neuropathies where antibodies have been isolated.  
In the case of anti-ganglioside antibody mediated neuropathy, antibody and MAC 
deposits are found at nerve terminals and nodes of Ranvier of motor axons 
following anti-ganglioside antibody-induced damage with anti-GM1  
(Greenshields et al.,2009; Susuki et al.,2007; Uetz-von et al.,1998) , anti-GD1a  
(McGonigal et al.,2010) and anti-GQ1b antibodies  (Halstead et al.,2004; 
Halstead et al.,2005b) .  Pathogenic effect of these antibodies was shown to be 
completely inhibited in experimental animal models by the administration of 
terminal complement inhibitors including APT070 and rEV576  (Halstead et 
al.,2005a; Halstead et al.,2008a; McGonigal et al.,2010), both in pathological and 
electrophysiological parameters.  
Recently, Halstead et al developed an in vivo mouse model of acute neuropathy, 
by the injection of anti-GQ1b antibody. These mice developed respiratory 
paralysis due to impaired phrenic nerve conduction, however the administration 
of eculizumab, an inhibitor of terminal complement, completely abrogated the 
paralysis  (Halstead et al.,2008b).   23 
 
 
1.5    Eculizumab 
Eculizumab is the first targeted complement inhibitor licensed for use in humans.  
It is a humanised IgG monoclonal antibody which specifically inhibits activation of 
the terminal complement system by binding to C5, thus preventing its cleavage 
into C5a and C5b, resulting in failure of MAC pore assembly. Since it acts at C5, 
it inhibits terminal complement regardless of the pathway of activation, and it 
leaves proximal complement, namely proteins C3a and C3b, preserving innate 
immunity.  
Eculizumab was developed and tested mainly in the complement driven 
haematological disorder paroxysmal nocturnal haemoglobinuria (PNH)  (Rother 
et al.,2007).  PNH is not an intrinsic autoimmune disorder, but is a condition 
caused by imbalanced complement activation at red cell surfaces. This occurs 
due to a genetic lack of the enzyme needed to make GPI anchor-protein, whose 
function is to anchor complement regulators, CD59 and CD55, to the cell surface, 
preventing inappropriate complement activation  (Parker et al.,2005). 
Uncontrolled MAC deposition on red blood cells leads red cell destruction and 
chronic anaemia in PNH.  The only curative option is allogenic stem cell 
transplantation, and prior to trials of eculizumab, patients were managed by 
recurrent blood transfusions. In two randomised control trials of eculizumab in a 
total 184 patients with PNH,  the median yearly blood transfusion requirement 
reduced from 10 to 0 with eculizumab treatment (Brodsky et al.,2008; Hillmen et 
al.,2006), and improvements were seen in fatigue and quality of life scores. 
Eculizumab lends itself well to trials in other complement-mediated conditions, 
and recent efficacy has been presented in some case reports in haemolytic-
uraemic syndrome associated with renal transplant (Chatelet et al.,2010; 
Zimmerhackl et al.,2010), results from larger trials for this indication are awaited.  
A substantial amount of safety data exists for eculizumab, since approximately 
820 unique patients to now have been exposed to eculizumab, in dosing 24 
 
regimens ranging from one day to almost six years, over a range of conditions 
including renal transplant, idiopathic membranous glomerulonephropathy, 
rheumatoid arthritis, psoriasis, and asthma  (Alexion Pharmaceuticals,2010).   
 
The most serious risk associated with eculizumab therapy is meningococcal 
septicaemia. Since eculizumab inhibits terminal complement, defence against 
encapsulated bacteria is reduced whilst on treatment.  There have been three 
reported cases of Neisseria meningitis infection, and one of these was in an 
unvaccinated patient  (Alexion Pharmaceuticals,2010).  This roughly equates to 
an incidence of 0.3% whilst on eculizumab. 
 
Other potentially life threatening risk of eculizumab treatment relates to 
immunogenicity of monoclonal antibodies. Although eculizumab is humanised 
and therefore less immunogenic than murine antibodies, immune-mediated drug 
reactions can occur.  The incidence of severe infusion reaction in eculizumab is 
estimated at around 8%, and in most cases successfully managed with pre-
medication (corticosteroid) and slowing the rate of infusion  (Dmytrijuk et 
al.,2008). Drug tolerance due to development of HAHAs (human anti-human 
antibodies) are low in frequency (3%)  with eculizumab treatment and considered 
to be not clinically significant as similar frequency is of HAHA found in placebo  
Other, less serious side effects are more common, including headache, 
nasopharyngitis, back pain, nausea, and upper respiratory tract infections.  In a 
large open-label study of 97 PNH patients receiving eculizumab, headache was 
the most common side effect, occurring in up to 56% of patients at the beginning 
of eculizumab treatment, and reducing to around 15% after 6 months of treatment 
(Brodsky et al.,2008). Further analyses of safety data show that the incidence of 
headache during the maintenance phase with eculizumab was the same as with 
placebo treatment and represents a 50% reduction as compared to the induction 
phase. 
Eculizumab has not yet been given in patients also receiving intravenous 
immunoglobulin, and safety data does not exist for this.  25 
 
1.6   Research aims 
The major research aim of the project was to conduct the first trial of a 
complement inhibition in humans with an immune-mediated neuropathy.  The 
complement inhibitor chosen was eculizumab, which is the first inhibitor of 
systemic terminal complement to be licensed for human use, and is now used 
widely in the treatment of paroxysmal nocturnal haemoglobinuria. A substantial 
amount of safety data exists for eculizumab, however, no trial has yet been 
published of terminal complement inhibition in any neurological condition, or of 
the co-administration of eculizumab with high-dose IVIg.   
Therefore, the aim of this study was not to determine the general safety of the 
eculizumab, but to discover any additional safety information arising from its 
administration in patients with immune-mediated neuropathy, or from its co-
administration with high dose intravenous immunoglobulin.  For this reason an 
open-label, pilot study design was chosen as the initial trial design. 
Multifocal motor neuropathy was chosen as the neuropathy to study as firstly 
there is clear evidence of a pathogenic antibody which is complement-fixing in 
neuropathy models, secondly it is a chronic condition which (in contrast to acute 
neuropathy) should be relatively stable over time and therefore lend itself study of 
intervention, and thirdly, patients are already known to be immune-responsive in 
MMN due to their responsiveness to IVIg.   
Secondary aims of this clinical trial were to discover any beneficial therapeutic 
effect by inhibiting complement in MMN. This effect would be measured by the 
reduced requirement for IVIg therapy, and by the clinical and functional outcome 
measures employed. 26 
 
2  Clinical trial: Methods 
2.1    Patients 
Patients were screened for eligibility from patients known to have immune-
mediated neuropathy, who were currently attending the short-stay ward for 
regular intravenous immunoglobulin, or attending neurology outpatient clinics at 
the study centre (Institute of Neurological Sciences, Southern General Hospital, 
Glasgow).  
2.2    Inclusion and exclusion criteria 
Core criterion for entry to the study were 
1)  Fulfilment of electrodiagnostic criteria for diagnosis of MMN with 
conduction block, either with definite or probable conduction block in at 
least one nerve segment. 
2)  Documented clinical improvement with intravenous immunoglobulin. 
3)  Ability to complete weekly self-evaluation functional rating scales. 
4)  Agreement to be vaccinated against meningococcal disease. 
5)  Ability to give informed consent. 
Core exclusion criteria were 
1)  Below the age of 18 years old. 
2)  Pregnancy, planned pregnancy or lactation. 
3)  Inability to comply with study related procedures or appointments. 
4)  Unresolved Neisseria meningitidis infection or history of meningococcal 
infection. 
5)  Known complement deficiency. 
6)  Any significant medical co-morbidity which was deemed to make the 
patient unsuitable for the trial.  
Patients who met the criteria above were invited to join the trial, given verbal and 
written information (see Patient Information leaflet, appendix 1). They were 27 
 
contacted at least 2 weeks following this to have further discussion, and then 
proceeded to give written consent.  
2.3    Study drug 
Eculizumab (Soliris™) was supplied by Alexion Pharmaceuticals, Cheshire USA, 
as a clear liquid in 300mg/30ml vials. The required dose was made up in 0.9% 
saline (Baxter™) to 5mg/ml, and infused via peripheral venous cannulae at a rate 
of up to 4ml (20mg) per minute. When eculizumab and IVIg were given on the 
same day, eculizumab was administered first, with a 2 hour interval before IVIg 
was given. Clinical trial nurses were employed to record patients’ vital signs 
before and during the infusion. Any signs of infusion reaction (hypotension, 
tachycardia, pyrexia, flushing, rash, bronchoconstriction, facial oedema, and 
stridor) were managed by stopping the infusion, clinical assessment of the 
patient, and administration of corticosteroids and antihistamine. The following 
dose could be given as scheduled if deemed safe by the investigator, but at a 
slower infusion rate, and following premedication with corticosteroids and 
antihistamine.  
2.4     Study design 
This was an open-label observational study. There were three trial periods, 
comprising an initial run-in period of maximum length 8 weeks, a 14 week 
treatment period, and an 8 week run-out period (Figure 2.1). At enrolment all 
patients were vaccinated with tetravalent meningococcal vaccine (ACWY Vax®, 
Glaxo Smith Kline). 28 
 
 
 
Figure 2.1. Study design flowchart 
 
The run-in period began on the date of a scheduled IVIg infusion, and for patients 
who were not receiving IVIg, at a mutually convenient date. On run-in day zero 
(RID0), full past medical history, clinical examination (vital signs, cardiovascular, 
respiratory, abdominal and neurological exam), and current medications were 
recorded in the patient clinical trial record. Clinical assessments (Table 2.1) were 
carried out in all patients. Electrophysiology was also performed at run-in day 
zero. IVIg infusion (Kiovig™) at dose of 1g/kg over 2-5 days was carried out as 
usual for each patient who already received IVIg.  
2.5   Clinical assessments 
Various trial assessments were employed. These were measured in all patients 
at baseline, treatment weeks 0, 4, 8 and 14, and finally at run-out week 8.  
Additional assessments were carried out in those patients receiving IVIg, as 
outlined below. 
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Muscle strength was assessed by two means, firstly a qualitative assessment 
using the widely clinically practiced MRC score.  Five muscles or muscle groups, 
each from two affected limbs, were chosen and scored from 0 (no visible 
contraction) to 5 (full active power against resistance), giving a total maximum 
MRC sum score of 50.  The 10 muscles or muscle groups were kept constant for 
each patient throughout each trial assessment. Quantitative measurement of 
muscle strength on a continuous scale was measured by myometry. Five 
clinically weak (MRC 3 or 4) muscles were chosen from each individual for 
myometry assessment, to be kept constant for each individual throughout the 
trial. A hand-held myometer (Lafayette™ manual muscle testing system, model 
01163) was used to measure the maximum force (kg) during isometric 
contraction, using the ‘break’ technique, in which both the tester and subject 
exerted maximal opposing strength until either the subject or the tester broke the 
contraction.  Three trials in each muscle were recorded.  
Table 2.1. Clinical Assessments 
1.  Medical Research Council (MRC)  sum score: total of 10 
muscle groups from 2 affected limbs 
2.  Muscle strength force (MSF) sum score: total of 5 muscle 
groups from 2 affected limbs, using myometry 
3.  Hand Grip Strength: using hydraulic dynamometer 
4.  Palm and pinch strength: using vigorimeter 
5.  Nine-hole peg test (9HPT): time to completion in seconds 
6.  10 metre walk: time to completion in seconds 
7.  Self Evaluated Functional Rating Scale (SEFR)  
8.  Overall Neuropathy Limitation Scale (ONLS) 
9.  European Quality of life scale (EQ5D) 30 
 
Overall hand grip strength was measured in kilograms using a hydraulic hand 
dynamometer (Jamar™). In addition, various-sized rubber balloons attached to a 
barometer (vigorimeter) were used to measure maximum palm and pinch 
strength (kiloPascals) in each hand. 
The nine-hole peg test comprised nine wooden pegs which were placed in 
corresponding holes in a wooden block. The time to completion of the test was 
recorded from contact with the first peg until the ninth peg was securely placed. 
Again, three trials each side were recorded at each assessment. For ease of 
interpretation, and to accommodate those who could not complete the test, this 
was converted to speed, expressed as percentage of test completed per second 
(100/seconds).  
The ten-metre timed walk was performed on a flat level surface using the 
patient’s usual walking aid (if any). This was also converted to speed, as 
percentage of test completed in one second (100/seconds). 
Quality of life scale (EuroQOL™ EQ5D, 1995) was used, which comprises a 
visual analogue scale from 0% (worst imaginable health) to 100% (best 
imaginable health), and a descriptive system which scores on five dimensions of 
living: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, 
giving a score between 0 and 1, where 1 is the value for full health.  The overall 
neuropathy limitation scale (ONLS) measured the limitation of activities of daily 
living usually affected by neuropathy, and provided a total score from 0 (no 
limitation) to 12 (full limitation, bed bound).  
The self evaluated functional rating (SEFR) score was central to the longitudinal 
assessment of patients throughout the trial. At run-in day zero the patient and the 
investigator chose 5 tasks of daily living that were affected by the condition, for 
example, using knife and fork together or lifting cup with left hand. These tasks 
were graded from 0 (normal) to 5 (impossible) based on the level of difficulty with 
this task.  Pre-printed SEFR score sheets were completed at the outset and tasks 
remained constant for the duration of the trial.  31 
 
Typically MMN patients, who are on maintenance IVIg regimes, experience a 
cyclical change in muscle strength due to the half life of IVIg, with an 
improvement in weakness 5 to 10 days after infusion, plateau of increased 
strength for some weeks, then subsequent decline heralding requirement for 
further IVIg.  The aim of using the SEFR score was to measure this effect, and 
allow its communication, in a standardised format, from the patient to the study 
team. It was expected that the SEFR score would be highest prior to IVIg dosing 
(indicating highest level of difficulty with chosen tasks), and lowest mid-cycle.   
SEFR score sheets were collected by the investigator weekly, by fax, email or 
completed over the telephone.  
2.6   Deterioration point criteria 
For patients receiving IVIg, the run-in period length was determined by reaching 
the deterioration point. 
Deterioration point criteria were defined (Table 2.2), the primary criteria being an 
increase in the SEFR score by at least 2 points above the baseline (RID0) score. 
This triggered clinical examination by the investigator, and if further deterioration 
point criteria were fulfilled, IVIg dose was scheduled. At this point, patients then 
entered the treatment period, and the first eculizumab dose was then given on 
day 0, prior to IVIg dosing.  
 
 
 
 
 
 
Table 2.2. Deterioration Point (DP) Criteria 
1.  SEFR score increase by 2 points from baseline 
Plus at least one of the following (2) to (6) 
2.  MRC sum score decrease by at least 1 point 
3.  Pinch/palm grip decrease by at least 10% (either 
side) 
4.  9 hole peg test time increased by at least 10% 
5.  10m walk time increase by at least 2 seconds 
6.  Patient/clinician feels deterioration has occurred 32 
 
 
Patients not receiving IVIg also completed weekly SEFR score sheets, however 
did not require to reach deterioration point prior to entering the trial, all completed 
the maximum 8 week run-in period.  
2.7   Electrophysiology 
Motor nerve conduction studies and electromyography were carried out in at least 
one affected nerve segment and muscle group, at baseline (RID0) and again at 
the end of the treatment period. The trial neurophysiologist was not involved in 
any other trial assessments. Data for distal latency (DL), compound muscle 
action potential (CMAP) amplitude and duration, conduction velocity, and F-wave 
latency were collected. Needle electromyography recordings (videos) of 
voluntarily contracting muscle activity were blindly scored by a panel of five 
qualified neurophysiologists, to assess any difference in the motor unit 
recruitment density between baseline and the end-of-treatment period. The 
recordings were presented in pairs (pre and post treatment) and assessors were 
blinded to the patient details and the ordering of the recordings. This resulted in a 
total score of minus 5 (all 5 examiners scored the post-treatment EMG less 
dense than the pre-treatment) to plus 5 (all 5 examiners scored the post-
treatment EMG more dense than the pre-treatment). 
 
2.8    Pharmacological tests 
Blood samples were collected at run-in day 0, then prior to every eculizumab 
dose (trough), 1 hour post dose (peak) and if IVIg was also given at same 
session, 1 hour into IVIg dose. Samples were immediately centrifuged at 3000 
rpm at room temperature for 10 minutes, the resultant supernatant was decanted 
into cryotubes, and stored at -80° C until being shi pped to Alexion laboratories, 
Cheshire USA.  Here pharmacokinetic (PK) and pharmacodynamic (PD) assays 
were performed. The PK assay measured serum eculizumab concentration 
(µg/ml), while the PD assay measured serum haemolytic activity (% of chicken 33 
 
red blood cells lysed by serum).  In addition, serum was collected for detection of 
human-anti-human antibodies (HAHAs). 
2.9   Detection of anti-ganglioside antibodies 
Enzyme-linked immunosorbent assay (ELISA) was used to detect anti-glycolipid 
antibodies to GM1, GM2, GD1b and GA1 in patient serum prior to trial 
commencement. These were not re-measured at trial completion. For ELISA 
methodology see section 5.2.1. 
2.10  Adverse events and safety reporting 
At each scheduled trial visit, patients were asked to report any symptoms, 
medical encounters or changes to medications.  During the treatment period, 
adverse event (AE) data was recorded weekly for the first 4 weeks, then 
fortnightly. During run-in and run-out periods, the AE collection interval varied 
between patients according to their visits, up to a maximum interval of 8 weeks 
from the previous visit.  Adverse events were graded as mild, moderate or 
severe, and their attribution to study drug graded 0 (unrelated), 1 (unlikely), 2 
(possibly), 3 (probably), 4 (definitely). Serious adverse events (SAEs) were 
reported within 24 hours to the local Pharmacovigilance office and to the Data 
Monitoring Committee (DMC).  Adverse events were defined as serious if they 
were fatal, resulted in or lengthened hospital admission, led to persistent or 
severe disability, congenital anomalies of birth defects.   
 
At enrolment, patients were issued with a detailed safety information card, which 
described the study and “alert” symptoms for meningococcal infection. Patients 
were counselled about the increased risk of developing meningococcal 
septicaemia whilst on eculizumab, and were asked to carry this safety card with 
them at all times during the treatment and run-out period. Alert symptoms were 
moderate to severe headache with nausea or vomiting, stiff neck or stiff back, 
fever, rash, confusion, severe myalgia with flu-like symptoms and photophobia. 
Clear instructions were given that patients should be seen by a physician at their 34 
 
local emergency department without delay.  24 hour emergency contact numbers 
of the trial doctors were listed on this card, for specialist advice. 
 
2.11  The role of the author 
My involvement in this clinical trial began following acceptance of the trial 
protocol by the ethics panel, therefore I did not contribute to the original protocol 
design. However, my role began by putting into effect the approved protocol. I 
screened and recruited patients, designed the data collection sheets for the 
clinical research files, liaised with research and enterprise, pharmacy and NHS 
staff and briefed colleagues and the clinical research nurses which were 
allocated to the study.  
Following recruitment, I collected all the baseline clinical data from patients. 
Thereafter, at each trial visit, I examined each patient as set out in section 2.5. 
Some of the timed assessments were also performed by the clinical research 
nurse(s), whose main roles were preparation the drug for intravenous infusion, 
performing measurements of vital signs (pulse, BP and temperature), logging 
information essential to drug accountability, and assisting with data collection and 
adherence to GCP (Good Clinical Practice) guidelines.  
At each trial visit I collected information about any adverse events and made 
clinical assessments as indicated. I then evaluated the potential causal 
relationship between study drug and adverse effect. Due to the increased risk of 
meningococcal septicaemia I was ‘on-call’ for patient queries, and they carried a 
safety card with my 24 hr contact number, so that themselves or any doctor 
treating them in an emergency could contact me for advice about suspected 
adverse reaction. 
Blood tests were taken at numerous time points which I then centrifuged in the 
lab to decant the serum for storage.  Following completion of the trial period, I 
sent all the data to the Robertson Centre for Biostatistics, who performed data 
cleaning and analysis. At this stage my involvement was dealing with data 
queries and liaising with the trial statistician about the analyses to be undertaken. 35 
 
Following this, I wrote the trial up for publication (see Appendix 2) and presented 
the findings at local, national, and international meetings.  
 
2.12  Ethics and monitoring 
The trial protocol and supporting documentation were approved by the regional 
ethical committee, and conducted in keeping with the Declaration of Helsinki. The 
trial is registered on EudraCT database (unique no. 2008-005748-18). The study 
was funded by Alexion Pharmaceuticals however remained an investigator-led 
trial, co-sponsored by the University of Glasgow and NHS Greater Glasgow and 
Clyde. A data monitoring committee (DMC) of three independent specialists was 
formed, who were provided with interim data and safety reports throughout the 
study. Only the DMC and the investigators had a steering role.  
 
2.13  Statistics 
Since the study was not designed primarily to test efficacy of this medication, no 
power calculation was performed, and the number of patients enrolled was 
merely a convenience sample based on the availability of eligible candidates with 
the condition.  
 
Individual data was collected on clinical research forms (CRF), and carbon copies 
were sent to the Robertson centre for Biostatistics (University of Glasgow), then 
entered into a study-specific database which was maintained by the Biostatistics 
department.   
Myometry or muscle strength/force (MSF) recordings were summed across all 5 
selected muscles for each patient to result in a total MSF score. 
Electrophysiology measurements were transformed to z-scores (excluding 
conduction block).  Z-scores were calculated for each nerve (anatomical location) 
by subtracting the mean and dividing by the standard deviation.  Thus a 
difference of 1 in z-score is a difference of 1 standard deviation across nerves.  36 
 
 
Task scores, speeds or values were summarized by median and inter-quartile 
range (IQR) values for each time point or period. The Wilcoxon signed-rank test 
was used to test whether the median differences in the intra-patient scores or 
speeds between the measurement points or periods and baseline (run-in day 
zero) were statistically significantly different from zero. The Mann-Whitney test 
was used to compare medians between unpaired groups. A p-value of 0.05 or 
less was considered to be significant. Statistical software packages used were R 
software version 2.9.0 (R Development Core Team, 2009), used by trial 
statistician where indicated in the text, and Minitab version 16 (Minitab Solutions), 
used otherwise by the author. Analyses performed by the trial statistician are 
acknowledged in the figure legends and text.  
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3   Results 
3.1    Patients 
25 patients with a prior diagnosis of MMN were screened, and 22 were 
considered eligible according to EFNS electrodiagnostic criteria and other 
inclusion criteria (see Figure 1.2 and Section 2.2). One patient was excluded from 
recruitment since he required air travel to reach the hospital. Another patient was 
diagnosed with metastatic cancer of unknown primary during the screening 
period and was therefore was not enrolled. 7 out of 20 patients declined 
enrolment due to a) potential risks of the trial drug and/or b) already receiving 
perceived full benefit from IVIg. 
The remaining 13 patients, who fulfilled all the additional criteria, were recruited 
to the study with informed consent. Basic clinical data are listed (Table 3.1).  
85% of patients in the trial were male (n = 11), and the mean age at entry was 56 
years (± SD 10 years). The mean length of disease by the start of the trial was 19 
years (± SD 10 years), and mean duration of IVIg treatment, in those receiving 
IVIg (n = 10, 77%), was 8.5 years (± SD 5 years). The median IVIg inter-
treatment interval was 4.0 weeks (IQR 3.0 – 4.8 weeks), and the mean dose in 
the year prior to the trial was 16.2 g/wk (IQR 5.8 – 19.2g/wk).  
Eleven patients (85%) had upper limb onset of weakness. The most common 
nerves affected were right median (77%), left ulnar (69%), left median (69%) and 
right radial nerve (62%). Six patients (46%) also had lower limb involvement, with 
common peroneal nerve involvement in 6, and tibial nerve involvement in 3 
patients (23%).  Five patients (38%) had sensory symptoms (numbness, 
paraesthesia), and 4 (31%) had minor sensory abnormalities on nerve conduction 
studies. Four (31%) had diminished reflexes in affected limbs only, whilst five 
(38%) had global hyporeflexia.   
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Table 3.1. Clinical Features  (n = 13) 
Male gender         11 (85%) 
Age at start of trial        55 years (IQR 51 - 65) 
Years affected by start of trial    19 years (IQR 10 - 29) 
Upper limb onset      11 (85%) 
Lower limb involvement  6 (46%) 
Sensory symptoms        5 (38%) 
IgM anti-GM1 antibody positive    9 (69%) 
IgM anti-GM1 antibody titre  1/9000 (IQR 1/1275 – 1/12500) 
Current IVIg treatment      10 (77%) 
Duration of IVIg treatment      9 years (IQR 5 – 14) 
Current IVIg inter-treatment interval 
   
4 weeks (IQR 3.0 – 4.75) 
Median IVIg dose per year  840 g/yr (IQR 300 – 1000) 
 
Seven patients had been tested for paraprotein (at some point in the past), and 
one had IgM paraprotein, kappa light chain, with high titres of IgM anti-GM1 
antibody. Anti-GM1 IgM antibodies were detected in 9 patients (69%), of which all 
were also reactive against GA1, and 6 (46%) against GD1a. Anti-GM2 IgM 
antibody was detected in 1 patient (8%) who also had reactivity against GM1.  
3.2   Safety 
No patient discontinued the study medication due to an adverse event. One 
patient had an aborted infusion due to an allergic response, with 
bronchoconstriction, tachycardia and rash, which was managed with prophylactic 
steroid and antihistamine before subsequent doses. This patient had a history of 
allergic response to IVIg, and routinely received pre-medication for this.  3
9
 
 
 
 
 
 
 
Figure 3.1. Study progress diagram. Each patient is represented by a horizontal line (numbered 
1 – 14 in vertical axis, note no patient 10 exists as this patient number was allocated to a 
patient who never reached enrolment). The shaded area in the middle shows the 14 week 
treatment period, whilst the unshaded areas to the left and right show the run-in and run-out 
periods. Events (IVIg given, adverse events) are marked at the corresponding week number 40 
 
There were four serious adverse events (SAEs) in total: two in the treatment 
period, and two in the run out period. All four were episodes of moderate 
headache accompanied by nausea (and dizziness in one case), which prompted 
these patients, in keeping with the high alert for symptoms of meningococcal 
disease, to seek medical attention. All patients were kept in overnight for 
observation. One case was investigated with lumbar puncture, revealing mild 
CSF lymphocytosis but no bacterial growth, in keeping with aseptic meningitis. 
Both SAEs which occurred during the treatment period, occurred 2 days following 
administration of IVIg and eculizumab together, however these patients reported 
that they had had similar headaches and nausea in the past with usual IVIg 
treatment, and would never usually report this or consult medical attention, but 
due to high alert state for meningococcal disease throughout the trial, they were 
obliged to do so. In both cases, symptoms were resolved fully within 48 hours. 
The two SAEs at week 8 run out period were in the same patient, for two 
separate hospital admission with moderate-severe headache, nausea, 
photophobia and dizziness. This patient had a previous diagnosis of labrynthitis, 
and this diagnosis was made. Symptoms improved with medical management. 
There were 5 adverse events in total during the run-in period, and these were 
reported in a total of 2 patients. In the treatment period there were 52 adverse 
events in total, reported by 11 patients. The treatment period was divided into two 
periods when reviewing the adverse event data, the induction phase TP 0-3 
(eculizumab given weekly) and the maintenance phase TP 4-13 (eculizumab 
given fortnightly).  There was a higher rate of adverse events reported in the 
induction phase of eculizumab treatment, with 7.25 AEs/week, compared to the 
maintenance phase, 2.3 AEs/week.   
To account for the inter-patient variation in run-period duration, the AE rate was 
expressed as the proportion of weeks per each period during which an AE was 
experienced by a patient (table 3.2). During the run-in period, the median 
proportion was 0% of weeks (IQR 0 – 0%), during the treatment period the 
median proportion was 14% of weeks (IQR 7 – 21%), and during the run-out 
period the median proportion was 0% of weeks (IQR 0 – 3%).  This means that 41 
 
during the treatment period, on average a patient experienced an adverse event 
during 14% of weeks (2 weeks) meaning that the remaining 86% (12 weeks) 
were on average, free from adverse events.  There was a significant increase in 
the AE rate during the treatment period compared to the run-in period (p = 0.004, 
Wilcoxon signed rank test) and run-out period (p = 0.007, Wilcoxon signed rank 
test). There was no significant difference between the AE rate during run-in and 
run-out periods (p = 0.79, Wilcoxon signed rank test). 
Of all 52 adverse events recorded during the treatment period, all except one 
(patient 8, diarrhoea, also experienced during run-in period) were treatment 
emergent signs or symptoms (TESS).  TESS are events which started following 
the administration of the study medication, such that any adverse event which 
had been present prior to receiving the medication could not be treatment-
emergent. The classification of an event as a TESS does not indicate the 
causality of the study drug to the event.  42 
 
 
Table 3.2. Summary table of adverse event characteristics. Brackets 
contain the number of AEs in that category, as a percentage all AEs in that 
time period. (Table produced by trial statistician) 
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Causality of adverse events to the study drug were graded by the investigator, 
and there were 2 AEs which were ‘definitely’ attributed to the study drug (infusion 
reaction, and subsequent rash), and 5 AEs which were ‘probably’ attributed to 
study drug (headache (n = 3), skin rash (n = 1) and pharyngitis (n=1). Overall 
during the treatment period, 28 AEs (54% overall) were classed as possibly 
related, 15 (29%) were unlikely to be related, and 2 (4%) were unrelated. 
Headache was the most common AE, accounting for 33% of all AEs during the 
treatment period. Almost two-thirds (11/17; 65%) of the headaches were in the 
first 4 weeks of treatment.  Nine patients (69%) experienced headache at least 
once during the treatment period.  Two out of the three patients who were not 
receiving IVIg, also experienced headache during the treatment period.  
Respiratory and coryzal symptoms (rhinorrhoae, pharyngitis) were responsible for 
7 (13%) of AEs during the treatment period, musculoskeletal (myalgia and 
arthralgia) accounted for 6 (12%), gastrointestinal symptoms (nausea, diarrhoea, 
constipation, and abdominal pain) accounted for 4 (8%) and skin rashes 
accounted for 4 (8%).  
The adverse event profile in patients not receiving IVIg was similar to those 
receiving IVIg. The most common was headache (n = 7). The others included 
joint pains (n = 3), malaise (n = 3), rhinorrhoea (n = 2), abdominal pain (n = 2), 
excess sweating, diarrhoea, leg cramps, bruising and hypertension (all n = 1). 
No unexpected treatment emergent signs or symptoms were noted.  No bacterial 
or other infections were encountered.  
The majority (73%) of AEs during the treatment period were classed as mild, and 
the remainder moderate (27%). No adverse event was classed as severe. The 
median duration of AE was 3 days (IQR 1 – 5). During the treatment period, AEs 
occurred at a median of 2 days post-eculizumab dose, and 2 days post-IVIg 
treatment. The three patients who were not receiving IVIg also experienced 
adverse events.   
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3.3   Pharmacological studies 
Median serum eculizumab concentration had increased to above the 35µg/ml 
minimum therapeutic level by treatment period week 1, and was maintained 
above this level throughout the treatment period. Pharmacodynamic (PD) 
analysis measured the terminal complement activity of patient serum, by its ability 
to haemolyse chicken red blood cells in vitro. A value of 100% haemolysis 
signifies that the collected serum has equal haemolysing ability as control human 
serum, therefore full terminal complement activity. Before Eculizumab treatment 
the median % haemolysis was 95% (IQR 77.5-98), whilst by week 1 this had 
reduced to 5% (IQR 2.75-19.5). 
Patients receiving IVIg had significantly lower median eculizumab concentration 
(78.7 µg/ml, IQR 55 - 108) compared to those not receiving IVIg  (119.7µg/ml, 
IQR 95 - 147). Importantly however, complete terminal complement inhibition in 
serum was achieved, with no difference between the median haemolytic 
complement activity in both groups (2% and 1% respectively).  The serum 
measurements were taken prior to Eculizumab or IVIG infusion, and therefore 
reflect the plateau state. There was no difference between the haemolytic 
complement activity pre-trial in patients receiving IVIg (median 98% haemolysis) 
and not receiving IVIg (median 94%) signifying that IVIg maintenance treatment 
did not affect terminal complement activity measured at the end of the IVIg cycle.  
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Figure 3.2. Pharmacological data depicted by boxplots, showing median 
value and interquartile range. Panel A. PK data: serum eculizumab 
concentrations (µg/ml). Panel B. PD data: serum haemolytic activity, % 
activity compared to control pooled normal human sera. Panel C and 
Panel D. Comparison of PK and PD data depending on patients receiving 
IVIg or no IVIg. Outliers shown by asterisks, were not excluded from 
analysis. Significance testing by Mann Whitney test. (Panel A and B 
produced by trial statistician) 46 
 
3.4    Intravenous immunoglobin requirements 
During the treatment period, 9 out of 10 patients receiving IVIg as maintenance 
therapy continued to require IVIg at regular intervals throughout the treatment 
period, which was qualified by reaching deterioration point.  
IVIg requirement was measured as the inter-treatment interval (in days) (Figure 
3.3). In the year prior to trial commencement, the median interval was 28 day 
(IQR 21 – 37). During the run-in period, the median interval was 30.5 days (IQR 
22 – 46). During the treatment period, the median interval was 35 days (IQR 23 – 
46), which was not significantly different to the run-in interval (p = 0.64) but was 
significantly different to the pre-trial interval (p = 0.006).   
 
Figure 3.3. Intravenous immunoglobulin requirements. Boxplots 
showing median inter-treatment interval (days) across the time points: 
prior, year preceding trial; RI, run-in period; TP, treatment period; RO, run-
out period. Significance testing carried out by Wilcoxon signed rank test.  47 
 
During the run-out period, the median IVIg interval was 31 days (IQR 22 – 44), 
this was neither significantly different to the treatment period (p = 0.15) nor the 
run-in period (p = 0.44).  The run-in and run-out periods were not significantly 
different from the pre-trial interval (p = 0.44 and 0.53 respectively), however the 
treatment period interval was significantly longer than the pre-trial interval 
(median difference 6.5 days, p = 0.006). Summarised, there was no significant 
difference between the IVIg inter-treatment interval in any of the trial periods, RI, 
TP and RO. There was no significant lengthening of the interval between pre-trial 
and RI, however there was a significant difference between pre-trial and 
treatment period, indicating a small net increase between RI and TP that was not 
statistically significant.   
The median of the average IVIg dose in the year preceding the trial, across all 13 
patients, was 16.2g/week (IQR 5.7 - 19.2), which is very similar to the median of 
the average weekly dose during run-in 16.3g/week (IQR 9.4 – 21.5) (p = 0.42).  
The average dose during the treatment period was 15g/week (IQR 0 – 23), but 
this was not significantly decreased from the run-in dose (p = 0.31). The run-out 
period dose was increased to 18.5g/week (IQR 9.5 – 2.5), but this was not 
statistically significant (p = 0.15). 
Patient 012, who did not require IVIg at all during the treatment period, had been 
receiving IVIg at 10 week intervals for 2 years prior to the trial.  During the run-in 
period, the 8 week maximum length was reached without deterioration, so patient 
012 entered the treatment period without receiving his next cycle of IVIg. During 
the treatment period, deterioration point criteria were not reached, in fact, SEFR 
score dramatically reduced (Figure 3.4), but during the run-out period increased 
to beyond baseline levels and IVIg was given again at week 7 of the run-out 
period due to reaching deterioration point. For the purpose of the analysis, patient 
12 is included in the IVIg treatment interval analysis below, with a run-in interval 
of 8 weeks, treatment interval of 14 weeks, and a run-out interval of 8 weeks, 
however the actual IVIg interval was 207 days (29 weeks).  A sensitivity analysis 
was carried out excluding and including patient 012, and there was no overall 
change to the significance of the comparisons of IVIg inter-treatment intervals.  48 
 
 
Figure 3.4. SEFR score of patient 012, who did not require IVIg between 
time points RID0 (run-in day zero) and ROW8 (run-out week 8), giving an IVIg 
interval of 30 weeks which spanned the three study periods. 
 
3.5   Muscle strength  
The MRC sum score did not differ significantly between any of the trial periods 
(Figure 3.5 Panel A). MRC sum score was also compared at successive 
deterioration points during the treatment period, and showed a non-significant 
trend to increasing score, from a median score of 23 (IQR 23 – 32) at the first DP 
to a median score of 28.5 (IQR 25 – 30) by the fourth DP (figure 3.6).  49 
 
 
Figure 3.5 Muscle strength measurements. Panel A, MRC sum 
score (out of total possible score 50). Panel B, MSF (muscle 
strength force/myometry) sum (kg). Boxplots displaying median 
score at individual assessment points. Significance testing 
compares to baseline (RIDO), Wilcoxon signed-rank test (Trial 
statistician). 50 
 
 
Figure 3.6. MRC sum score at successive deterioration points 
during the treatment period in patients receiving IVIg. Median MRC 
sum score across patient (n = 9).  Significance testing by Wilcoxon 
signed rank test. 
 
The MSF (myometry) score steadily increased at each successive assessment 
point (Figure 3.5 Panel B), and was significantly higher than baseline (median 
35kg, IQR 25 - 42) at treatment week 8 (median 43kg, IQR 38 – 52, p = 0.01) and 
week14 (median 44kg, IQR 31 – 59, p = 0.01), and run-out week 8 (median 44 
kg, IQR 30 – 48, p = 0.02).  The increase between run-in period and treatment 
week zero was non-significant (p = 0.13). There was no significant difference 
between treatment period overall, and run-out week 8 (p = 0.73).   
To control for any ‘learning’ effect between RID0 and TPW0, assessments were 
also compared to TPW0, rather then RID0, and the similar increase was found, 
also significant.  
Median pinch grip strength (vigorimetry) showed small but significant changes at 
week 4 in both sides, but this difference was not seen at any other time point 
(Figure 3.7 Panels A and B). There were no significant changes in median palm 
grip strength throughout all periods (Figure 3.7 Panels C and D). Whole hand grip 51 
 
(dynamometry) similarly did not show any overall trends, and there were no 
significant differences at any assessment points.  
 
Figure 3.7. Pinch and palm grip (vigorimetry). Boxplots of median pinch 
(A and B) and palm (C and D) grips for each side at study time points. 
Significance testing compares to baseline (RIDO), Wilcoxon signed-rank 
test (Trial statistician). 
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3.6   Timed assessments 
 
Figure 3.8. Timed assessments. Panel A shows timed 10m walk 
expressed as speed in percentage of total completed in 1 second (100/s). 
Panels B and C display the speed of completion of 9 hole peg test, 
expressed as percentage of test completed in 1 second. Significance 
testing compares to baseline (RIDO), Wilcoxon signed-rank test (Trial 
statistician). 
 
The timed walk speed did not differ from baseline throughout the treatment period 
(Figure 3.8 Panel A), save for a slight dip at treatment week 0, which was non-
significant (p = 1.0). Patient 006 at baseline took 21 seconds (speed 4.8/sec) to 53 
 
complete 10m (and was using a stick for balance), at week 14 completed this in 
14 seconds (speed 7.14/sec) without walking aids. This improvement in timed 
walk did not vary with IVIg dosing, and had further improved to 12 seconds by the 
end of the run-out period.           
 
In the nine hole peg test (9HPT) the right hand was faster than the left hand at 
baseline (right hand 2.9/sec, left hand 1.8/sec) (Figure 3.8 Panels B and C).  
There was a significant increase in 9HPT speed of right hand between baseline 
and all treatment time points (including TPW0),  equating to an overall 21% 
increase in the speed of completion by week 14 (p = 0.01).  There was no 
significant change from treatment to run-out period (p = 0.50). The left hand 
9HPT speed was significantly different only at week 4.  There was a significant 
increase right, but not left 9HPT speed from run-in day zero to the start of the 
treatment period (median increase 0.4/sec, p = 0.05).  Analysis using TPW0 as 
the baseline time point shows speed increases in both hands which were smaller 
and less significant.  
3.7   Subjective assessments 
Overall, there were improved SEFR scores (i.e. numerically reduced) week by 
week throughout the treatment period. This trend can be seen in Figure 3.9. The 
SEFR score was significantly improved from baseline at week 8 (median 
decrease 1 point, p = 0.03) and week 14 (median decrease 3 points, p = 0.02). 
There was no significant difference between run-in period and run-out period 
SEFR score, indicating that once eculizumab treatment finished, patient rated 
difficulty with daily tasks increased again.  54 
 
 
Figure 3.9. SEFR score. Mean SEFR at each week throughout all trial 
periods is plotted, with connecting line between means. Error bars show 
95% confidence intervals. TP0-14 = treatment period week 0-14, RO = run 
out period. (Trial statistician) 
Baseline median EQ5D analogue scale response was 70% (IQR 60 – 81) and 
significantly increased to 75% (IQR 70 – 90) at week 4 (p = 0.04), and was 
equally, but non-significantly, raised at later treatment time points (Figure 3.10 
Panel A). The EQ5D health utility showed no change in the median score 
throughout the treatment period compared to baseline (median 0.7 throughout) 
(Figure 3.10 Panel B).  
The median score ONLS score remained at 4 (IQR 4 -5) throughout all time 
points, the minimum and maximum scores showing no variation (Figure 3.10 
Panel C). 55 
 
 
Figure 3.10. Subjective assessments. Panel A shows EQ5D visual 
analogue scale representing perceived health in percentage at study 
assessment points. Panel B shows EQ5D health utility score, for 
description see text. Panel C shows ONLS (Overall Neuropathy Limitation 
Scale) total score at study assessment points. Significance testing 
compares to baseline (RIDO), Wilcoxon signed-rank test (Trial statistician). 
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3.8    Responders versus non-responders 
In a post hoc exploratory analysis, patients that had a minimum SEFR score 
during the treatment period which was at least 2 points lower than the minimum 
SEFR score during the run-in period (i.e. subjectively improved with daily tasks 
during eculizumab treatment) were retrospectively classed as ‘subjective 
responders’. Using this criterion, 7 of 13 (54%) of patients were subjective 
responders: of these 5 of 7 had subsequent increase in SEFR score by at least 2 
points during the run-out period, indicating that this SEFR score decrease was 
only seen whilst on eculizumab in these patients.  
The seven subjective responders included 2 patients not receiving IVIg. 
Comparison of trial assessments at baseline and at time points between 
responders and non-responders reveals a difference in the measurements 
between these two groups. No statistical analysis has been performed since this 
was a post-hoc descriptive analysis, but the pattern suggests that those who had 
subjectively responded to treatment with eculizumab also had higher MRC score 
and myometry recordings at baseline (Figure 3.11). They also had greater hand 
functionality with faster 9HPT speeds and greater pinch-grip strengths at the 
outset. The responder group appears to have had an increased IVIg inter-
treatment interval from run-in period to treatment period, while the non-responder 
group shows a slightly decreased interval.  57 
 
 
Figure 3.11. Responders vs non-responders. Boxplots displaying values 
for two groups of patients, no (clear box) = subjective non-responders (n = 6), 
and yes (shaded box) = subjective responders (n = 7), at time points RI (run-
in day zero) and TP (values averaged throughout treatment period). Panel A 
shows IVIg inter-treatment interval .Panel B shows MRC sum score and MSF 
sum score showing responders. Panel shows pinch grip for right and left 
hands. Panel D shows nine hole peg test (time to complete in seconds). 
Asterisks represent outliers in the data. 
 
3.9    Electrophysiology 
Approximately two motor nerves from each patient were studied by nerve 
conduction studies. The median conduction block (expressed as % CMAP 
amplitude reduction) at run-in was 36% (IQR 27 – 53), and at treatment week 14 
had significantly reduced by median 6.5% (IQR 2.5 – 11.5, p = 0.05) (Figure 
3.12). The distal latency Z-score also showed a small but significant decrease at 
the end of treatment, by median 0.16 standard deviations (p = 0.05).  This 
equated to a decrease in distal motor latency from 5.5 seconds (IQR 3.6 – 6.1) to 58 
 
4.7 seconds (IQR 3.7 – 5.9).  There was no change in the conduction velocity, 
proximal CMAP, distal CMAP or F-wave latencies between nerves.  
 
 
Figure 3.12. Electrophysiology. Interval plots showing individual values 
for each nerve studied (total of 22 nerves from 13 patients) motor nerve 
conduction studies. Panel A shows conduction block expressed as the 
percentage decrease in voltage between distal CMAP to proximal CMAP, 
across a nerve segment. Panel B, distal CMAP amplitude expressed in 
mV. The two time points for the studies were RI (run-in day zero) and TP 
(end of the treatment period).  
 
To test whether conduction block and distal CMAP had changed over time in this 
group, 1 nerve segment showing conduction block was selected from each 
patient from trial baseline studies, and values for percentage conduction clock 
and distal CMAP amplitude were compared with those from the last available 
historical study of that nerve segment. The median interval in this comparison 
was 5 years (IQR 2 – 6), and the median percentage conduction block was 51% 
in both the previous and the current studies (IQR 41 – 87 previous; IQR 37 – 83 59 
 
current). There was a non-significant trend to lower median distal CMAP with 
time, (4.0mV previous; 2.7mV current, p = 0.17).  
 
Figure 3.13. Comparison of conduction block and distal CMAP 
amplitude changes over the pre-trial period. Line plots showing 
individual values for conduction block (left panel) and distal CMAP 
amplitude (right panel) across 11 nerves with conduction block from this 
cohort of patients, CB 1 and CMAP 1 values refer to the last available 
nerve conduction studies prior to trial inclusion. CB 2 and CMAP 2 values 
refer to the baseline studies recorded for this trial. Significance testing by 
Wilcoxon signed rank test.  
Electromyography studies of a maximum voluntary contraction were compared by 
being assessed blindly by a panel of 5 neurophysiologists. 22 muscle groups (2 
from each patient, n = 11, 2 patients excluded as recordings were not available at 
time of assessment). Out of 22, only 6 muscle groups received unanimous 
scorings, four showing increased motor unit recruitment and two showing 
decreased recruitment following treatment. 60 
 
 
4  Discussion 
4.1   Safety 
This trial did not set out to further clarify the absolute safety of eculizumab, as this 
has already been done, but was designed to assess if a complement inhibitor 
could be co-administered in patients receiving IVIg, and whether there were any 
unexpected adverse events with this combination.  Overall, this study observed a 
significant increase in the rate of adverse events during eculizumab treatment, 
compared with run-in period.  Around 10% of these were classed as definitely or 
probably related to the study drug. Most of the adverse events were mild, the 
remainder moderate in severity. None were severe, and no patient discontinued 
treatment due to adverse events.  There were two serious adverse events whilst 
on treatment, which became classed as ‘serious’ adverse events due to 
heightened awareness of meningococcal meningitis, leading to reporting of ‘alert’ 
symptoms (headache), and the subsequent need for investigation and  
hospitalisation for these two episodes.  Overall, the most common adverse event 
was headache, which made up 33% of the adverse event profile, and occurred at 
least once in 69% of patients.  The rate of occurrence of headache was higher 
than the TRIUMPH study  (Schubert et al.,2008), a prominent phase III 
randomised control trial of eculizumab in PNH, which found 44% of patients had 
headache during eculizumab treatment. Perhaps the increase seen in this trial is 
due to the co-administration of IVIg, as headache is also the most side effect of 
IVIg treatment.  The other most common adverse events encountered in this 
study were (in descending order) respiratory, musculoskeletal, gastrointestinal 
and dermatological. This compares well to data from other studies with 
eculizumab, and there were no unexpected AEs which were thought to be 
possibly related to treatment.  There were no cases of meningococcal 
septicaemia in this group, and no other bacterial infections noted. Furthermore, 
no patients experienced a worsening of disease, an important point given that 
corticosteroids are known to be deleterious in MMN.  61 
 
However, there were some difficulties with the interpretation of the safety data 
findings of this study. Firstly, this trial was not placebo-controlled, and therefore 
we do not know how frequently these adverse events would be reported in this 
same group of patients whilst not receiving eculizumab. Secondly, the heightened 
alert for meningococcal disease led to increased reporting of headaches. Thirdly, 
the frequency of adverse event reporting was not constant throughout the three 
phases of this trial, as the reporting in the run-in period was from 3 up to 8 weeks, 
however in the treatment period, investigators and patients met at least weekly, 
and thus there was greater prompting and opportunities for reporting of mild 
events.  
Overall, in this short duration open label study, it was observed that eculizumab 
treatment was associated with an increase in adverse events, of which none 
were unexpected side effects, and were roughly in keeping with safety data from 
previous studies.  There is evidence thus, that co-administration of eculizumab 
and IVIg, may be associated with slightly higher rate of adverse events, but is 
well tolerated.  
4.2    Pharmacokinetic and pharmacodynamics 
Pharmacological assays demonstrated that terminal complement function was 
fully inhibited in all patients, regardless of concomitant IVIg use, and thus there 
was no neutralizing effect of IVIg upon eculizumab.  However it was found that 
patients receiving IVIg had lower median eculizumab concentrations. Eculizumab 
is expected to be eliminated via the same pathways as are native human 
antibodies, being too large to be renally excreted, even in the context of nephrotic 
syndrome, they are taken up into endothelial pinocytotic vesicles containing FcRn 
receptors, also known as the ‘Brambell’ receptor.  The Brambell hypothesis is 
precisely this, that IgG homeostasis is regulated by the FcRn receptor which 
salvages IgG (but not IgA or IgM) and prolongs the life-span of IgG, and 
regulates its recycling.  (BRAMBELL et al.,1964). Mice genetically lacking 
expression of FcRn demonstrated IgG hypercatabolism and faster IgG 
elimination  (Ghetie et al.,1996).  62 
 
The pharmacokinetics of IgG immunoglobulins is known to be non-linear, 
displaying concentration-dependant elimination  (Lobo et al.,2004) and this has 
been shown for therapeutic monoclonal antibodies also  (Tabrizi et al.,2006). The 
rate of catabolism of immunoglobulins is increased when higher concentrations 
are present, and this is thought to explained by the Brambell hypothesis, as at 
lower concentrations, a larger proportion can be ‘salvaged’ by the FcRn receptor, 
but at higher concentrations there are less available receptors and thus IgG 
remains in the circulation where it is more likely to be catabolised. It has 
previously been thought that patients receiving high dose intravenous 
immunoglobulin will show higher rates of catabolism of IgG antibodies, due to 
saturation of FcRn receptors  (Yu et al.,1999). Animal models where monoclonal 
antibodies were administered, followed by high dose IVIg (2g/kg), resulted in an 
increased rate of excretion of the monoclonal antibody  (Bleeker et al.,2001), and 
extrapolated to humans, this predicts a 25% increase in elimination of the 
monoclonal antibody within 3 to 4 weeks.   
A highly possible explanation for the finding in this study, of lower eculizumab 
concentrations in patients receiving high dose IVIg, is due to concentration-
dependent elimination, and therefore further supports the Brambell hypothesis. 
However it is clear from the data presented here that although this occurs, 
pharmacodynamics and this serological efficacy of this antibody were not 
compromised.   
It is thought that perhaps this effect this also accounts for some of the therapeutic 
effect of IVIg in antibody-driven autoimmune conditions, by increased elimination 
of the autoantibody, as a result of saturation of the salvaging mechanism by 
exogenous IVIg.  In myasthenia gravis and stiff-person syndrome, IVIg treatment 
results in the decline in AchR-Ab  (Illa,2005) and anti-GAD antibodies 
respectively  (Dalakas,2005). However the same does not hold true for MMN  
(Piepers et al.,2010), most likely because the antibody is IgM isotype, and 
therefore is not regulated by the FcRn receptor. 63 
 
The MMN response to IVIg, but not to other immunomodulatory methods, may be 
due to the complement regulating effects.  Antibodies against several 
components of the classical complement pathway have been identified in IVIg. 
They include antibodies against C1, C3a, C3b and C4  (Jacob et al.,2009). In 
addition, high doses of IVIg are thought to enhance the degradation of C3b  (Lutz 
et al.,1996).  It has now been shown in vitro (using ELISA) that IVIg decreases 
complement deposition by IgM-GM1 antibodies in vitro, and results in decreased 
classical pathway activation in MMN patients receiving IVIg  (Piepers et al.,2010).  
The results presented here show that IVIg maintenance therapy did not reduce 
the haemolytic activity (MAC lysis effect) in MMN patient serum, as this was 
>90% in patients regardless of IVIg therapy when patient serum was tested at 
baseline, prior to eculizumab treatment. However, the samples from this assay 
were collected immediately prior to the next dose of IVIg, and thus perhaps since 
the effect of IVIg has since declined, and any changes to complement have 
returned to baseline. It would be interesting to test MMN patient serum mid-cycle 
for complement levels. This effectively did happen during the eculizumab 
treatment period, but complement was already fully suppressed by eculizumab, 
and remained inhibited even at the end of the dosing window. Hence, even if IVIg 
does cause a decrease in terminal complement activity in MMN, by replacing this 
effect more robustly with eculizumab, there still remained a need for IVIg. From 
this it could be concluded that the overriding IVIg therapeutic effect in MMN is 
mediated by factors other than complement activity.  There are many other 
immunomodulatory roles of IVIg: interference anti-idiotypic antibodies interfere 
with the binding of autoantibodies to their target ligand, reducing the formation of 
immune complexes, modulation of macrophages function via modulation of Fc 
receptors, and modulation of cytokines and cell signalling molecules in the 
humoral and cellular immune reaction.  
Another possible reason for lack of IVIg replacement by eculizumab could be that 
terminal complement inhibition was not fully achieved in the endoneurial 
compartment, since this is separated from plasma by the blood-nerve barrier 
(BNB), and we do not know what proportion of eculizumab was able to cross this. 64 
 
Schwann cells and macrophages are known to synthesise C5 locally  (Ramaglia 
et al.,2009), thus the combination of lower intraneural eculizumab concentration, 
and higher C5 concentration, may reduce the pharmacodynamic properties of 
eculizumab in this compartment.  In addition, Schwann cell expression of 
complement regulators such as CD59 may also be fully up-regulated in MMN to 
the extent that additional terminal complement inhibition may have little effect on 
the ongoing injury. 
Regarding the passage of immunoglobulins across the BNB, in animal models of 
Guillain-Barré syndrome, radiolabelled immunoglobulin was increased 3-4 days 
into the disease, but declined by day 8.  MMN is a chronic condition, in this group 
the median disease duration was 19 years, and there are multifocal lesions of 
different ages throughout various motor nerves. Perhaps the permeability of the 
blood-nerve barrier is increased in the acute lesion, but returns to baseline in the 
chronic phase, and thus eculizumab and other immunoglobulins cannot enter all 
sites of conduction block.   This however still leaves the question of why IVIg 
works effectively in MMN.  
4.3    Secondary outcome measures 
Although complement inhibition did not replace the requirement for IVIg, some 
improvements in secondary outcomes were observed. There was an overall trend 
towards improvement in patient-rated subjective scores whilst receiving 
eculizumab, and in approximately half of the group eculizumab treatment 
decreased their difficulty with tasks of daily living more than usual with IVIg.  
Eculizumab also benefited two patients who were not receiving IVIg, displayed by 
changes to SEFR scores in these two patients.  
There was an overall trend towards increased muscle strength as measured by 
myometry, which did not diminish during the run-out period. The maintenance of 
muscle strength during the run-out period could have represented longer lasting 
benefit from eculizumab, which could be proposed to occur through remyelination 
of some nerve fibres.  65 
 
Speed of 9HPT completion significantly increased in the right hand with 
treatment; although this could have been a practice effect, and was not seen in 
the left hand. However, other objective clinical measurements did not show any 
clear trends, even when responders and non-responders were considered 
separately.  
Half of the patients who were subjective responders, although still requiring IVIg, 
reported the pre-treatment deterioration points (DPs) were less severe, as scored 
by SEFR, and the MRC sum score improved during these DP compared to their 
previous DPs. One patient who routinely received 10 weekly IVIg did not reach 
deterioration point at all during eculizumab treatment, making the inter-treatment 
interval 30 weeks in total, and whilst the SEFR scoring greatly improved, no 
improvements in objective measurements were noted in this patient.  
There are some difficulties in the evaluation of MMN as a condition, the most 
prominent reason is due small numbers of patients with this condition. Additional 
difficulties are introduced due to the multifocal nature of this neuropathy, resulting 
in a slightly different anatomical pattern and severity distribution in each patient, 
and thus there is no global set of assessments that can be broadly compared 
across the heterogeneous group of patients. Discrepancies between subjective 
and objective outcome trends, has been previously noted in MMN trials  (Leger et 
al.,2001).  Few articles have been published on the best outcome measures to 
evaluate patients with MMN, and those selected here were based on clinical 
experience with neuropathy, knowledge of tools used well other published MMN 
trials, for example SEFR score  (Van den Berg et al.,1995).  Since MMN is an 
upper limb predominant disease, multiple measures of hand strength were 
employed in this study, and dexterity was also measured by the 9HPT.  However, 
due to same hand side being compared across the whole patient group, 
unaffected hands in some patients were compared with affected hands in other 
patients, which could cause the collective data to mask smaller changes in 
affected muscles. As proposed during the ENMC (European Neuromuscular 
Centre) International workshop on selection of outcome measures for peripheral 
neuropathy clinical trials  (Merkies et al.,2006), modified sum scores are used 66 
 
here where possible, choosing the most affected muscles in each patient. This 
can explain the observation in this study, that myometry and SEFR scores were 
those to show a convincing trend, since these tests was individualized for each 
patients depending on their most affected muscle groups and functions.  
Outcome measures in this study were also likely to be affected by the inter-test 
variability introduced by random fluctuations in patient performance and operator 
or device measurement errors. In a series of MMN and CIDP patients, controls 
limits analysis was performed on myometry data with the aim of describing the 
variability within this group, and found that almost 90% of patients had variability 
of up to 30%  (Lough et al.,2000).  Coupled with the suggestion that the minimally 
clinically important difference in a measure could be as low as 8%  (Jaeschke et 
al.,1989), the chances of discovering this within data from neuropathy trials could 
be extremely low due to the high levels of inter-test variability. 
An additional level of variability introduced in this study was IVIg therapy, as this 
is known to cause cyclical changes to muscle strength  (Van den Berg et 
al.,1998), which were also noted in some, but not all, patients in this trial.  Due to 
fixed assessment points in this study design, patients were assessed at varying 
points in their cycle, so intra- and inter-patient comparisons were also likely to be 
difficult to interpret.  Due to this, outcomes measures were compared, in a 
separate analysis, at successive deterioration points only, which were thought to 
represent a fixed ‘trough’ level of function as assessed by patient and clinician. 
No significant differences in measures compared at deterioration points were 
found, although there was a pattern of increasing MRC sum score at deterioration 
points.  
The finding that subjective responders had a higher level of pre-trial function and 
muscle strength in comparison with subjective non-responders suggests that 
patients who were less severely affected were more likely to experience an 
eculizumab-related treatment response. It should be equally recognised that the 
eculizumab non-responders still remained responsive to IVIg, and so these 
patients were not treatment-resistant. Motor axon loss is an important 67 
 
determinant of weakness in MMN and the degree of axonal degeneration 
increases with disease duration  (Van Asseldonk et al.,2006; Van den Berg-Vos 
RM et al.,2002a).  As has also been shown in CIDP  (Iijima et al.,2005) and MMN  
(Nobile-Orazio et al.,2002), muscle atrophy and electrophysiological evidence of 
axon loss, are more likely in patients who are not responsive to IVIg.  Therefore it 
would be not only intuitive, but also evidence-based, to aim this and other novel 
therapies towards less advanced cases where more scope for a treatment 
response exists. 
4.4   Electrophysiology 
Electrophysiological measurements are important here as they represent the only 
objective assessments collected in the study that were independent of patient-
related performance bias.  There were improvements in individual measurements 
in some patients, and deterioration in others, but with an overall trend in favour of 
improvement, by a small but significant net decrease in the degree of conduction 
block across all nerves studied. It would not be expected that conduction block 
would change appreciably over time, and the median conduction block had 
remained stable in these nerves studied for a median of 5 years before the study, 
yet within 14 weeks of treatment, there was a significant change.  The effect of 
IVIg on conduction block remains unresolved, as some studies show 
improvement in conduction block with IVIg treatment  (Van den Berg-Vos RM et 
al.,2002b; Vucic et al.,2004), whilst in others no electrophysiological changes 
were found, despite improvements in muscle strength in by up to 80%  (Leger et 
al.,2001).  This could be explained by an improvement in nerve conduction at 
sites not measured by nerve conduction, such as those more proximal or more 
distal to the segment studied. There was a significant change in distal motor 
latency, which suggests that distal conduction was slightly faster.  This may well 
represent resolution of distal conduction block at micro sites in the small nerve 
fibres in the hands and feet. It has been proposed that this occurred in 4 out of 18 
nerves studied with long term IVIg treatment, and is thought to be due to 
remyelination  (Van den Berg-Vos RM et al.,2002b). However, this effect was not 
observed in the nerves as a whole, as there was no significant change to 68 
 
conduction velocity, or F wave latency, other parameters which would be 
expected to improve with nerve remyelination, and thus this effect may have 
been length dependent. 
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4.5   Conclusion and future work 
 Overall, in this short duration open label study, it can be concluded that co-
administration of eculizumab and IVIg did not highlight any additional safety 
concerns, and IVIg did not reduced the pharmacological effectiveness of 
eculizumab. There was some evidence of small positive benefits of eculizumab 
treatment in MMN. This was observed in some, but not all, of the subjective and 
objective measurements used. The outcome measures that were most tailored to 
assess each individual showed the most significant changes.  In addition, truly 
objective measurement using electrophysiology, showed some small but 
significant improvements in nerve conduction.  It is difficult to come to any overall 
conclusion about the efficacy of eculizumab in multifocal motor neuropathy, due 
to the uncontrolled study design and the lack of dramatic response seen (such as 
large reduction in amount of IVIg required), however it can be viewed as 
encouraging for further studies of complement inhibition in MMN and other 
immune-mediated neuropathies.   
Ideally, a longer term study of terminal complement inhibition should be 
performed in MMN, looking for a more gradual cumulative effect or an arrest of 
disease progression. When considering future studies, placebo controlled trials 
designs would be clearly be the next step for the investigation of this drug, in 
order to control for test performance variability, learning effects, and operator and 
patient-related assessment bias.  
Perhaps more pressing than future trials in MMN, would be a trial in acute, 
severe neuropathy such as Guillain-Barré syndrome in which early aggressive 
treatment has a greater capacity to majorly influence short and long-term 
morbidity, and more evidence for the beneficial effect of complement inhibition 
from animal models exists. Now that safety data regarding the co-administration 
of IVIg and eculizumab exists, a trial of complement inhibition in Guillain-Barré 
syndrome is a high priority. 70 
 
5  Laboratory work: Investigating the serological factors in MMN 
5.1    Introduction  
The knowledge that up to 50% of patients in MMN do not possess antibodies to 
GM1, may place some doubt over the theory that MMN is an antibody driven 
disease  (Nobile-Orazio et al.,2005), although it remains clear that MMN is a 
immune-mediated disease since antibody-negative patients are also largely 
immune-responsive.  
5.1.1  Anti-GM1 antibody in MMN 
There are some alternative theories to explain the significance of GM1 antibodies 
in this disease, for example, that the GM1 antibody is a biomarker for disease, 
produced when inflammation of the nerves exposes GM1-rich areas of nerve to 
immune cells and thus antibodies develop. A similar explanation is that GM1 
antibodies are present as markers of previous infection with Campylobacter jejuni 
or other organisms which may have similar cross-reactivity with GM1. However, 
much evidence exists to support the theory that immune attack of nerves is 
mediated by anti-GM1 antibodies, via complement fixation, causing destruction of 
peripheral nerve structure and function. This has been demonstrated in vivo and 
ex vivo for not only the anti-GM1 antibody  (Greenshields et al.,2009; Nobile-
Orazio et al.,2005; Yuki et al.,2001), but for anti-GD1a antibodies   (Goodfellow et 
al.,2005; McGonigal et al.,2010) and anti-GQ1b antibodies  (Halstead et 
al.,2005a; Halstead et al.,2008a; Halstead et al.,2008b).  As support for the 
antibody-driven theory, the anti-GM1 antibodies found in MMN are demonstrated 
in vitro to be specific for motor nerves, though sensory nerves do contain GM1 
gangliosides, the antibodies from MMN sera do not bind  (Corbo et al.,1992). It is 
perhaps no coincidence that MMN is a predominantly motor condition.  The 
binding site on the GM1 antibody found in MMN perhaps therefore has specificity 
for a particular structural arrangement of GM1 which seems to be specific for 
GM1 in motor nerves although GM1 ganglioside is found in non-neural tissue 
types within the body. 71 
 
The fluid mosaic model of the cell membrane helps us to understand that lipids 
and proteins diffuse easily in a bilaminar phospholipid layer  (Singer et al.,1972), 
and thus the conformation of the gangliosides in this environment are not fixed, 
although it is known that gangliosides exist in lipid clusters  (Fujita et al.,2007). 
Current methods of antibody detection, ELISA and combinatorial microarray both 
described in this paper, are conducted in the ‘solid phase’, and therefore detect 
antibodies which bind to glycolipids which have been immobilised on a fixed 
plane.  
5.1.2  Glycolipid complex microarrays  
Current work in the investigation of autoimmune neurological conditions uses 
combinatorial microarrays to assess the effect of glycolipid pairings on antibody 
binding in the solid phase, thereby imitating the effect of glycolipid clustering on 
the cell membrane. Using this method, novel antibody sensitivities have been 
discovered, for example, sulfatide:ganglioside interactions in CSF from patients 
with multiple sclerosis (Brennan et al, unpublished data), and many 
ganglioside:ganglioside pairings in serum from patients with GBS  (Kaida et 
al.,2004; Kaida et al.,2007).  The explanation for this new reactivity is that the 
pairing of the two lipids creates a novel epitope which matches the binding site of 
an antibody already present in serum from the disease population. This may 
reflect a configuration of lipids on the nerve membrane within the lipid clusters via 
which that antibody exerts pathogenic effects.  Previous work within our research 
group has demonstrated that the ability of anti-GM1 antibodies to bind to target 
tissue is affected by its local glycolipid environment, and that GM1 is often 
inaccessible due to the presence of terminal sialic acid residues on neighbouring 
gangliosides  (Greenshields et al.,2009).  This work has primarily involved two 
mouse IgG monoclonal antibodies (DG1 and DG2) both with similar binding 
affinities for GM1.  DG1 was developed by harvesting of the immunogenic 
response to lipopolysaccharide isolated from Campylobacter jejuni, and DG2 
using a GM1-bearing liposome as the immunogen.  DG2 bound to the live ex-vivo 
nerves and exerted pathogenic effects via MAC deposition, whilst DG1 did not, 
unless the nerves were treated with neuraminidase which altered the ganglioside 72 
 
composition of the nerve membrane by removing terminal sialic acid residues 
(see Figure 5.1). Greenshields also used a monoclonal IgM antibody cloned from 
a patient with MMN  (Willison et al.,1994), and this showed similar binding 
requirements as DG1. 
 
 
Figure 5.1. Schematic illustration of the effect of neuraminidase on 
gangliosides with terminal sialic acid. Neuraminidase cleaves the terminal 
sialic acid residue, leaving a terminal ganglioside configuration identical to 
GM1.  
5.1.3  PC12 cells 
PC12 phaeochromocytoma cells are clonally derived from rat adrenal medullary 
tumour cells, originally generated by Greene and Tischler in 1976   (Greene et 
al.,1976).  PC12 cells are small round cells, diameter 6-14µm  (Tischler et 73 
 
al.,1978), which is comparable in size with human red blood cells.  Grown in vitro 
they have morphologic and cytochemical features in common with normal 
chromaffin cells, synthesising and storing catecholamines and acetylcholine, and 
bearing sympathetic nervous system receptors  (Tischler et al.,1978). Further to 
the development of the cell line, it was discovered that PC12 cells also bear 
nerve growth factor (NGF) receptors, and when this is added to culture, it causes 
cessation of cell division and development on neuronal cell qualities, with 
branched processes (neurites), electrical excitability via activation of Ca
2+ and 
Na-K
+ channels, and development of synapses between cells. Therefore, the 
cells undergo morphological and physiological changes with the addition of NGF 
which transforms them into neurones similar to those of the sympathetic nervous 
system  (Fujita et al.,1989).  Sialic acid bearing gangliosides account for 10% of 
the lipid weight of the PC12 cell, and this approximately doubles with NGF-
induced differentiation. Tri- and tetra-sialogangliosides make up the biggest 
proportion of gangliosides, with mono and di-sialogangliosides also present  
(Walton et al.,1988; Wu et al.,1988). Although the total amount of gangliosides 
increases with neural differentiation, the ganglioside repertoire and their relative 
amounts do not change  (Walton et al.,1988). 
5.1.4  Neuraminidase 
Neuraminidases are naturally occurring enzymes that cleave the glycosidic 
linkages of neuraminic (sialic) acids  (CARUBELLI et al.,1962). The most 
characterised is its role as a virulence factor in influenza, and this has led to the 
development of therapeutic neuraminidase inhibitors, such as oseltamivir 
(Tamiflu™) to prevent virus mobility and penetrance  (Jefferson et al.,2010). It 
has been demonstrated to cleave terminal sialic acid groups, thus converting 
GD1a and GT1b to de novo GM1 (Figure 5.1), in a variety of ganglioside-
containing tissues, including red blood cells  (Ackerman et al.,1980), neural tissue  
(Wang et al.,2009) and PC12 cells  (von et al.,2001). 
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5.1.5  Cholera toxin B subunit 
Cholera toxin is a heat-labile enterotoxin secreted by diarrhoeal bacterium Vibrio 
cholerae, and less classically, by Escherichia coli  (Van Heyningen et al.,1976).  
It is composed of two subunits A and B. Each complex contains 5 B-subunits 
arranged in a pentamer, and one A-subunit with a long tail that sits within the 
central pore of the B-subunit pentamer-complex. Cholera toxin binds to intestinal 
epithelium via B-subunit binding GM1 on the cell surface. Upon binding the A-
subunit is released and enters the cells, resulting in increased adenylate cyclise 
activity, cAMP production and massive secretion of water and electrolytes leading 
to profuse watery diarrhoea  (Bennett et al.,1975).  
Cholera toxin B subunit (CTB) is widely used experimentally as a reliable probe 
for GM1 ganglioside, and the binding affinity is remarkably high with dissociation 
constants (KD) in the 10
-10 to 10
-12 M range  (Kuziemko et al.,1996) (which is 10
4 
to 10
6 fold higher than the anti-GM1 monoclonal antibodies used in the following 
experiments). Regarding the specificity of the CTB-ganglioside interaction, there 
is some evidence to suggest that CTB may cross react with other gangliosides, in 
particular asialo-GM1 (GA1) and GD1b, however with low avidity and 
requirement for high concentrations of these other gangliosides  (Cumar et 
al.,1982; Lauer et al.,2002). 
5.1.6  Fluorescence-activated cell sorting (FACS) analysis 
FACS analysis uses flow cytometry to detect the fluorescence and structural 
characteristics of individual cells (or particles) within heterogeneous mixtures, 
and thus has potential to sort the cells into different groups by their 
characteristics or different fluorescent labels.  Flow cytometers are custom built 
machines which propel the cells or particulate mixture in a focused stream, via an 
arrangement of lasers, and fluorescence detectors, which are perpendicularly 
arranged and detect direct light emittance (forward scatter) and deflected light 
(side scatter),giving information about the size and the complexity of the cell 
structure  (Fulwyler,1980).  75 
 
5.1.7  Research aims 
The aim of this experiment was to screen a database of MMN sera, to determine 
the different binding characteristics which may exist within this seemingly 
homogenous group and through this perhaps elucidate more clues to the 
antibody’s pathogenicity.  First the aim to was discover any anti-GSC 
(ganglioside complex) antibodies in MMN patients, through the use of  novel, 
miniaturised solid phase immunoabsorption study (microarray), which could 
facilitate the screening of larger cohorts of membrane lipids than traditional 
ELISA techniques.  
Secondly, the binding characteristics of IgM anti-GM1 antibody in MMN sera 
were sought, in particular, looking for an inhibitory effect of local GD1a as was 
discovered with human monoclonal antibody from an MMN patient.   
5.2    Methods 
5.2.1  ELISA 
Ganglioside stock solutions for ELISA were made by diluting gangliosides in 
methanol to 2µg/mL. 96 well ELISA plates (Immulon 2HB) were ‘coated’ with 
gangliosides by adding 100µL per well, and for the negative control methanol 
only was added to a number of wells per ELISA plate. Subsequently, the plate 
was left to air dry for at least 2 hours in a fume hood. Plates were kept at 4° C for 
at least 1 h prior to further use. 
Plates were blocked with 2% BSA/PBS for 1 h at 4° C. Primary samples were 
diluted in 0.1% BSA/PBS. Then 100µL of the diluted solution was applied to each 
coated well of the ELISA plate. Incubation was for 12 h at 4° C. 
The primary solution was discarded, and the plates immersed in cold PBS were 
then discarded for five cycles. IgM peroxidase-labelled secondary antibody was, 
diluted 1:3000 in 1% BSA, and 100µL applied to the wells and incubated for 1 h 
at 4° C. The plates then underwent the same wash pro tocol as for the primary 
solution. Detection was performed with an o-phenylenediamine dihydrochloride 76 
 
solution. The reaction was terminated with 50µL of 4 M H2SO4. Optical density at 
492 nm was detected by an automated plate reader (Ascent Multiscan, 
Labsystems, GMI, USA). Background (methanol) optical density (OD) values 
were subtracted to give final OD values. 
 
5.2.2  Microarray 
Screening of combinatorial lipid arrays was performed as previously described  
(Rinaldi et al.,2010). Sera from 33 patients with MMN were screened on a 
microarray panel comprising lipid membrane components GM1, GM2, sulphated 
galactosylceramide (sulfatide), galactocerebroside (GalC), phosphatidylserine 
(PS), GD1a, GT1b, GA1, sulfoglucuronyl paragloboside (SGPG) and sialosyl-
lactoneotetraosylceramide (LM1) (Sigma, UK or Avanti Polar Lipids, Alabaster, 
AL). These were solubilised in methanol and immobilized on a PVDF membrane 
(Invitrogen, UK) alone and in combinations (a 1:1 v/v mixture comprising 10ng of 
each lipid per spot) using an automated TLC arrayer (Camag Linomat 
Autosampler). Membranes were blocked with 2 % bovine serum albumin (BSA) in 
PBS (10 mM Na2HPO4, 150 mM NaCl, pH=7.4) for 1h. Membranes were then 
incubated with 250 µl of serum diluted in 1 % BSA in PBS for 1 h at 4°  C. After a 
further wash cycle, membranes were incubated with 250 µl of a 1:25000 diluted 
HRP-labelled anti-human IgM antibody for 30mins and washed twice in 1% BSA 
in PBS. The membranes were dried for 10 minutes at room temperature and 
chemiluminescence signals were detected (ECLplus, GE Healthcare) by 
autoradiography. Exposure time was 1 minute. 
5.2.3  PC12 cell culture 
Culture flasks were coated with poly-l-lysine (Sigma-Aldrich) diluted to 4mg/ml in 
PBS.  Culture medium was made as follows: for each 100ml,  7.5ml FBS (foetal 
bovine serum, Sigma), 7.5ml horse serum, 1ml   penicillin/streptomycin (GIBCO 
15140), 1ml L-glutamine 200mM (GIBCO), and remainder, 83ml DMEM 
(Dulbecco’s modified eagle medium, GIBCO). The serum-enriched culture 
medium was filtered and stored at 4° C until use. PC 12 cells were grown in culture 77 
 
flasks at 37° C in water jacketed CO 2 incubator until around 80% confluence was 
reached, with culture medium changed every 48-72 hours. 
5.2.4  Immunohistochemistry 
Culture medium was removed from the flasks and flasks were rinsed with PBS 
(pre-warmed to 37° C), before being trypsinised at 3 7° C for 1-2mins to detach 
cells from the coated surface of the flasks. Serum-enriched culture medium was 
added to the flasks to suspend trypsinisation, and the cell-containing medium 
was added to sterile universal containers, centrifuged at 900rpm for 5 minutes. 
The supernatant was discarded and the cell pellet re-suspended in 5ml culture 
medium using a 23 gauge needle. Cells were then counted under the microscope 
to give cell concentration per ml.  20,000 cells were pipette onto the centre of 
poly-l-lysine coated glass cover slips, and once cells had adhered to cover slip, 
wells were filled with culture medium, and placed in the 37° C for 24 hours.  
Neuraminidase (Sigma-Aldrich) was made up to concentration of 2 units/ml (1 
unit = 128µg) in serum-free DMEM, and warmed to 37° C prior to adding to the 
culture wells, which had been pre-rinsed with serum-free DMEM. Cell-coated 
cover slips were incubated with neuraminidase for 30 mins at 37° C. Following 
this, cover slips were rinsed with 4° C PBS, and kep t on ice.   
The immunostaining step follows. In preliminary experiment, to establish the 
presence of GM1 ganglioside on neuraminidase treated and untreated cells, 
FITC-labelled cholera toxin B subunit (Vibrio cholera, Sigma-Aldrich C9903) was 
made up to concentrations of 250ng, 500ng, 1µg and 2µg and incubated in 
darkness at 4° C for 60 mins.  In further experiment s, unlabelled CTB was 
incubated as above, at concentration 1µg/ml, prior to incubation with monoclonal 
antibodies (DG1, DG2 and SM1) 10 µg/ml, or MMN sera at 1:10, 1:50 and 1:100 
dilutions.  Following this, FITC-labelled secondary antibodies were applied at 
1:300 concentrations for 30mins; for DG1 and DG2 goat anti-mouse IgG3-FITC 
(Southern Biotech) and for MMN, control sera and SM1 mAb, goat anti-human 
IgM-FITC (Southern Biotech).  78 
 
 Cover slips were then washed in 4° C PBS, and then fixed with 4% 
paraformaldehyde, left for 15mins at room temperature, then Triton-X100 0.1% 
was added to permeabilise the cells. Cover slips were rinsed in PBS and 
mounted on microscope slides with addition of DAPI mounting medium for 
nuclear staining (Vectashield, Vector). Image acquisition was performed using 
Carl Zeiss software, exposure time was kept constant for each image.  
5.2.5  FACS analysis 
Following the trypsinisation step above, cells were re-suspended in serum free 
DMEM and 5 x 105 cells were added to 12mm diameter polyester round bottom 
tubes (BD Falcon). Neuraminidase treatment was carried out as above. Following 
this, FACS tubes were centrifuged at 4° C 500rcf  in  FACS buffer (recipe) for 
rinsing, prior to addition of 5µg unlabelled CTB (initially 2µg but increased later in 
experiment due to lack of blocking of sera – see results).   Cells were rinsed twice 
in FACS buffer between CTB incubation, and addition of MMN sera, 
concentration 1:50. This was the optimum concentration found on cells staining 
(above) to have detectable binding to cells with low background binding. Cells 
were washed 3 times in FACS buffer by resuspension of the pellet between 
successive centrifugations, before incubation with secondary antibody (FITC-
labelled as above, 1:3000).  All FACS analyses were carried out on the same 
FACScalibur machine, each sample recorded at least 10,000 cells. Using FlowJo 
software, mean fluorescence intensities were calculated.  
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5.3   Results  
5.3.1  Combinatorial microarray 
MMN sera from 33 patients were screened on a 10 x 10 combinatorial microarray 
composed of the lipids GM1, GM2, GD1a, GT1b, GA1, GalC, SGPG, Sulphatide, 
LM1 and phosphatodylserine (PS), giving a total of 45 lipid complexes, each 
duplicated in a mirror image against a diagonal line of methanol only as shown in 
figure 5.2.  
 
Figure 5.2.Combinatorial glycolipid microarray. Two microarray images 
are shown with superimposed layout grids for ease of interpretation. Boxes 
marked ‘X’ represent spots where methanol only, no lipid, was spotted 
onto the PVDF. Along the outer horizontal and vertical rows are the single 
lipid spots, duplicated in a mirror image across the methanol only line. All 
other spots represent lipid combinations as per the corresponding 
row/column headers. The microarray depicted on the left side is a typical 
anti-GM1 positive patient, who has binding detectable to GM1 single, 
which is seen to be diminished by combinations with GD1a, GT1b and 
LM1, whilst enhanced in combinations with GalC notably. Whilst on the 
right, a typical anti-GM1 negative patient is depicted, showing no binding 
to any single lipid, but binding to the following combinations of lipids: 
GM1:GalC, GM2:GalC, GA1:GalC and SGPG:GA1. 
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5.3.2  ELISA vs microarray 
The widely employed threshold in ELISA above which a value is regarded 
positive is 0.1 OD (which is derived from screening a large pool of healthy control 
serums at intervals and in-house quality control checks)  (Willison et al.,1999). 
Two methods for positive value threshold were proposed. First, the median and 
95% confidence interval of GM1 single in the healthy control population was 
calculated by Wilcoxon signed rank test (data was not normally distributed) giving 
an estimated median of 460 intensity units (IU), with a 95% confidence interval of 
341 to 654 IU. Thus any values above 654 IU were considered to be positive for 
GM1 single on the microarray. As can been seen from figure 5.3, there was 
concordance between ELISA and microarray results such that ELISA negative 
sera were microarray negative, and positives likewise, except for one patient who 
was positive on the microarray (mean intensity 3996 ± 1086) whilst negative on 
the ELISA (mean OD 0.09 ± 0.03).  
 
Figure 5.3. Correlation between ELISA and microarray for GM1 
single. Both panels display the same scatterplot of individual values which 
are mean binding intensity (of repeated experiments) for 32 individual 
patient sera in ELISA and microarray testing for GM1 single epitope. In 
both plots, regression analysis was performed, and the solid line 
represents the best fit line, whilst the dotted lines represent reference lines 
on the corresponding axes, where value above the line would be 
considered positive. In both panels, the reference line on the x-axis 
(ELISA) is 0.1 OD, the origin of this value is explained in the text. The two 81 
 
scatterplots here differ by the choice of two different reference lines for 
microarray method. Panel A uses the value 654 IU, which is the upper 
95% confidence interval of the median binding intensity to GM1 single by 
the cohort of 27 healthy controls. Panel B uses the value 4365 IU, which is 
the predicted value of binding intensity which corresponds to an ELISA 
value of 0.1 OD, calculated by the regression equation presented in the 
text.  
There was a linear relationship between ELISA and microarray values, such that 
the regression equation was  MICROARRAY (IU) = 387 + (39780 x  ELISA (OD)), 
on linear regression analysis the p value of the correlation coefficient was < 
0.001, and R
2 was 59.2%, indicating a good fit of this regression line. From this 
equation the corresponding microarray value to the widely used positive cut-off 
value of 0.1 OD on ELISA can be predicted.  Thus a value of 0.1 OD would be 
(387 + (39780 x 0.1) =) 4365 IU on microarray testing. Since an OD of 0.1 is the 
upper limit reference point for the diagnostic lab, then perhaps the corresponding 
microarray value should also be used as the cut-off for a positive result. If we do 
this, the yield of GM1 positives is reduced, to 19/33, and as can be seen from 
figure 5.3 panel B, there are now two samples which had been positive on the 
ELISA but were negative on the microarray.   
5.3.3  GM1 binding in complex with other glycolipids 
Using the former method, the upper 95% confidence interval of the median as the 
cut-off, there are 25 sera which are positive on the microarray for GM1 single, 
equating to 76% of the MMN population screened. The median signal intensity of 
GM1 single epitope was 13394 IU (IQR 5213 – 28801).  When GM1 was in 
complex with other gangliosides or glycolipids, the signal intensity increased, 
decreased or was unchanged as shown in figure 5.4. The complex-inhibiting 
lipids were (in order of inhibition) LM1, GD1a, and GT1b. The complex-enhancing 
lipids were (in order of enhancement) GalC, SGPG and sulphatide.  82 
 
 
Figure 5.4. GM1:glycolipid complex binding Boxplots are drawn, each 
depicting the median change in binding intensity from GM1 single and the 
corresponding GM1 complex. Shaded boxes represent interquartile range, 
whiskers represent the remaining upper and lower 25% of the data, while 
outliers are represented by circles with diagonal crosses through the 
centre. Outliers were not excluded from any analyses. Boxplots where the 
majority of the data falls below the zero line are considered to be complex 
inhibited, while those which lie above the zero line are considered to be 
complex-enhanced.  
5.3.4  GM1:GalC association with disease 
Binding to GM1:GalC lipid combination was found in 100% of MMN sera, 
regardless of reactivity to GM1.  ANOVA of the significance of the difference 
between MMN (all sera) and healthy controls reveals that the combination 
GM1:GalC is the most significantly different in the MMN group compared with the 
control group, with a p-value of 6.38x10
-17 was GM1:GalC. As can be seen in 
figure 5.5, this epitope had the highest fold change from the healthy control 
group, and was more sensitive than even GM1 single epitope (since it was 
present in all MMN sera regardless of GM1 positivity).  83 
 
 
Figure 5.5. Glycolipid moieties associated with MMN disease vs 
healthy controls 
Scatterplot where individual dots depict the statistical data for the epitope 
(single or paired glycolipids) comparing the binding intensity of MMN sera 
to healthy control sera for that epitope. Dots are plotted at x values 
representing the inverse size of the p-value, where the negative value of x 
is the number in scientific notation of power-of-ten, thus a larger x-value 
means a smaller decimal of p-value, thus stronger significance.  The fold 
change value (y-axis) is calculated by the binding intensity in the MMN 
sera divided by the binding intensity in the healthy control sera.  
 
Examining the GM1:GalC complex further, there was clear complex 
enhancement with GalC in the GM1 positive sera. The mean intensity of the 
complex was significantly higher by 8797 IU (95% confidence interval 2538 – 
15056), than if the intensity of each single spot was added together (GM1:GalC 
complex vs. GM1 single + GalC single, paired t-test, p=0.008). In the GM1 
negative group this complex enhancement is greater, at 10734 (95% CI 2595 – 
18873). The above can be seen illustrated in figure 5.6.  84 
 
 
Figure 5.6. GM1:GalC complex enhancement. Bar charts display 
microarray data of the mean value of binding intensity for the epitope 
shown, plus the 95% confidence interval for the mean (error bars). ‘GM1 + 
GalC’ was calculated by adding the value of GM1 single to the value of 
GalC single in each individual, whereas ‘GM1:GalC complex’ is the real 
value obtained on microarray testing of that glycolipid pair. Panel A 
displays this data for the GM1 negative population (n = 7) whereas panel 
B displays the data for the GM1 positive population (n = 25). Paired t-tests 
were used to derive p-values for the difference between the expected 
binding intensity from the addition of the two singles, and the observed 
binding intensity.  
 
 
5.3.5  Immunohistochemistry of PC12 cells 
Immunohistochemistry was performed as a qualitative experiment to test the 
antibody and serum binding to the cell membrane. First the cells were incubated 
with fluorescence-labelled cholera toxin B subunit, to demonstrate GM1 epitope 
presence on the cells. This showed that GM1 was present in both the untreated 
and treated PC12 cells. 85 
 
 
Figure 5.7. Fluorescent-labelled Cholera toxin B in neuraminidase 
treated cells. Images showing immunohistochemistry staining of PC12 
cells. DAPI staining (blue) is specific for the cell nuclei, and FITC-staining 
(green) appears to be binding to the cell membrane, and in this case is 
conjugated with cholera-toxin B subunit used as a probe for GM1 
ganglioside on the cell surface. Different concentrations of FITC-labelled 
CTB were applied (500ng left side; 1µg right side) to cells which were 
neuraminidase treated (row B) and those which were not (row A).  CTB 
can be seen to bind the cells regardless of CTB treatment, and this is 
effective at both concentrations of CTB.  
 
Next monoclonal antibodies were studied, human IgM GM1 antibody (SM1) and 
mouse IgG monoclonal antibodies DG1 and DG2. SM1 been shown on 
ganglioside-complex microarray, to be 100% inhibited from binding to GM1 by 
being in complex with GD1a or GT1a, similarly too, DG1 reacted in this pattern, 
whilst DG2 binding was not complex inhibited and bound to GM1 in the 
microarray in a complex independent manner. Figure 5.8 shows that both DG1 86 
 
and SM1 did not bind untreated cells, however did bind to the cell surface 
following removal of sialic acid residues by neuraminidase treatment, and this 
binding was blockable by incubating treated cells with unlabelled cholera toxin B.  
It is shown, by the binding of labelleled CTB and DG2 antibody to untreated 
PC12 cells, that GM1 is present, and potentially bindable, on the cell surface 
before neuraminidase treatment. As can be seen in figure 5.8, binding of DG2 
was also blockable by unlabelled CTB.   
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Figure 5.8. Binding of anti-GM1 monoclonal antibodies to PC12 cells 
treated with neuraminidase. Immunohistochemistry images with nuclei 
stained blue (DAPI) and green fluorescent staining (FITC) corresponds to 
binding of the monoclonal antibody depicted in columns (left to right DG1, 
DG2 and SM1).  In row A the cells are untreated and have had no 
incubation with cholera toxin, simply incubated with monoclonal antibody 
then with secondary FITC labelled antibody. Row B shows cells which 
have been treated with neuraminidase prior to incubation with mAbs and 
labelled secondary antibody. Row C shows cells which have been treated 
with neuraminidase then incubated with unlabelled cholera toxin B prior to 
being incubated with the monoclonal and labelled secondary antibody.  
Using unpurified human serum from MMN patients, binding to PC12 cells was 
investigated, and similarly found that sera only bound to cells which had been 
neuraminidase treated, however binding did not seem to be ‘blockable’ by CTB. 
Serum from patients with MMN who were IgM GM1 antibody negative were also 
studied, and this revealed no binding to either treated or untreated cells.  88 
 
 
Figure 5.9. Binding of MMN sera to PC12 cells treated with 
neuraminidase. As before, PC12 cells are stained with DAPI (blue) 
nuclear staining, and FITC-labelled (green) secondary antibody binds to 
the primary antibody (MMN sera). ‘MMN 10’ and ‘MMN 24’ (first two 
columns) are sera from patients who are known to be IgM-anti-GM1 
positive on ELISA and microarray. ‘MMN neg serum’ (final column) is 
serum from a patient known to be IgM-anti-GM1 negative. As before, cells 
in the second and third rows have been treated with neuraminidase, and 
only the cells in the final row have been pre-incubated with unlabelled 
cholera toxin B subunit. 
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5.3.6  FACS analysis 
Fluorescence activated cell sorting was employed as a quantitative measure of 
the above experiments. Essentially, the same experiments as shown in the 
immunohistochemistry above were repeated using FACS methodology.  Using 
the monoclonal antibodies, antibody binding to the cells was able to be quantified 
in terms of the fluorescence of a cell population. Mean fluorescence intensities 
(mean fluorescence unit, MFU) were calculated from cell populations of 10,000 
(~8000 after gating), and divided by the background fluorescence intensity to 
provide a proportion of background fluorescence. For DG1 and SM1, there was 
no binding above background levels of fluorescence therefore can be expressed 
as 0 MFU. Both DG1 and SM1 were demonstrated to bind to neuraminidase 
treated PC12 cells, with mean fluorescence rising to 890 MFU (± SD 142) and 
991 MFU (± SD 159), which is between 14 and 18.5 times the background 
fluorescence or the binding to untreated cells. Antibody binding to treated cells 
was completely blocked by pre-incubation with cholera toxin B-subunit, with 
mean fluorescence in this cell population (minus background fluorescence) of 0 
MFU, for both DG1 and SM1.  
DG2 showed a different pattern, and was able to bind to untreated cells with 
intensity up to 20 times higher than background, with mean fluorescence intensity 
of 1298 MFU (± SD 207). The binding of DG2 to neuraminidase-treated PC12 
cells was over double the binding to untreated cells (3068 FU ± SD 398 vs. 1298 
MFU untreated), which was fully blockable by cholera toxin to fluorescence 
intensity roughly equal to that of the untreated cell population (1023 MFU ± SD 
163) . For this monoclonal, the effect of cholera toxin on untreated cells was 
investigated, and this blocked just over 50% of the binding of DG2 to untreated 
cells (580 MFU ± SD 85).  90 
 
 
Figure 5.10. FACS analysis of neuraminidase-treated PC12 cells 
Histograms overlaid on the same graphs are drawn for each monoclonal 
antibody tested on Flow cytometry. The x-axis is the mean fluorescence 
intensity, which is a direct measure of the antibody binding to the cell (and 
thus to GM1 ganglioside on the cell surface). The y-axis displays the 
number of cells which were counted in the corresponding fluorescence 
range, standardised across all three cell groups overlayed on the same 
graph, as the percentage of the maximum number of cells counted across 
all three groups. In all three panels, the green line is the histogram for 
fluorescence intensity of untreated cells, the red line is that of 
neuraminidase treated cells, and the blue line is the histogram of 
neuraminidase treated and cholera toxin pre-incubated cells.  Where a line 
shift to the left we can say that binding in that population was lower, 
whereas line shifted to the right represents higher binding. 
 
Following this initial experiment, the next step was to investigate the binding of 
MMN sera to these cell populations (neuraminidase treated PC12 cells), with the 
aim to characterise whether the binding of the anti-GM1 antibody in MMN sera 
could be enhanced by neuraminidase treatment. Sera from 16 patients, which 
were known from microarray and ELISA to be IgM GM1 antibody positive, were 
tested. SM1 was used as a standard during each run of the experiment to ensure 
there was concordance between the cell populations and the efficacy of 
neuraminidase treatment.  Thus the MFI value for SM1 binding to neuraminidase-
treated PC12 cells was used as the ‘maximum binding intensity’ for each run. 91 
 
Differences between cell cultures were corrected for by expressing the 
fluorescence as a percentage of this maximum binding intensity for each run. The 
mean maximum binding intensity across all runs was 1052 IU, 95% confidence 
interval 690 – 1413 IU.  
Overall, the binding intensity (as % of maximum) increased from 13% to 26%, a 
significant increase of 12.7% (95% confidence interval 1.8 to 23.7, p = 0.02).  
There was a mean fold change for treated vs untreated cells of 2.0 (95% 
confidence interval 1.3, 2.8), thus there was on average a doubling of binding 
intensity when treated with neuraminidase.  
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Figure 5.11. The effect on neuraminidase treatment of MMN sera 
binding to PC12 cells. Binding intensity is expressed as percentage of 
the maximum binding intensity for that run of experiments, which was SM1 
binding to neuraminidase treated cells. Panel A and B show the mean 
percentage binding intensity for the 3 cell groups overall, and the 95% 
confidence intervals of the mean, in anti-GM1 positive (Panel A) and anti-
GM1 negative patients (Panel B). In panel A, significance testing by paired 
t-test, showed significant difference between untreated cells and treated or 
untreated cells and treated plus CTB pre-incubated.  In panel B 
significance testing revealed no significant differences between cell 
groups. Panel C shows the binding intensity of 16 anti-GM1 positive MMN 
sera with lines showing the trend between cell groups for each individual 
serum tested, where ‘treated’ means neuraminidase treatment and ‘CTB’ 
means cells were incubated with cholera toxin prior to addition of the 
serum.   
 
Incubation of cholera toxin B following treatment with neuraminidase but prior to 
incubation with patient sera did not show the full blocking effect that was 93 
 
demonstrated with the monoclonal antibodies, as can be seen in figure 5.11 
panel A, the binding intensity remained as high as the treated cells without 
cholera toxin.  Significance testing between the two groups, treated and treated 
plus CTB incubated, unsurprisingly revealed no difference between groups of 
CTB incubation or no incubation. (p = 0.69, paired t-test).   
By looking at the individual trend for each patient sera (figure 5.11 panel C) we 
can see that there was one in particular (subject ID MMN 10) which behaved 
similarly to DG2 and SM1, in that binding increased with neuraminidase 
treatment (from 14% untreated to 98% treated). It was partially blocked by 
subsequent cholera toxin binding (42%). This gives a mean fold change for this 
individual of 6.9 (± SD 3.9).  
We divided the mean fluorescence intensity (MFU) of the CTB incubated cells, by 
the MFI of the non-CTB cells, giving a ratio, where a value of less than 1 meant 
that CTB blocked some of the binding of the sera to the neuraminidase treated 
cells. This data was not normally distributed, and Wilcoxon signed rank test was 
used to calculate the estimated median ratio to be 1.06, with a 95% confidence 
interval 0.8 to 1.6.  5 sera had a ratio of less than 0.8 and therefore we can say 
were partially blocked, whilst 3 sera had ratio above 1.6, displaying further 
increase of sera binding with incubation of CTB.   
A control group of MMN sera known to be negative for IgM anti-GM1 antibody 
(figure 5.11 panel B) showed low degree of binding to untreated cells, which did 
not increase with neuraminidase treatment (p = 0.7, paired t-test). 
 
5.3.7  Correlation between solid-phase and fluid phase membrane binding 
characteristics 
Correlation studies were performed using data from the glycolipid complexes 
analysis, to search for any relationship between the increase in binding with 
neuraminidase treatment (measured fold change mean fluorescence in treated 
cells over the mean fluorescence of untreated cells) and the percentage inhibition 94 
 
of solid phase GM1 binding when in complex with GD1a.  This revealed that an 
inverse relationship existed, where the regression equation was ‘fold change = 
12.39 – 0.1 x % inhibition’, such that that the lower the inhibitory effect of GD1a 
on GM1 binding, the higher the increase in binding to PC12 cells with 
neuraminidase treatment. This is the converse of what was logically suspected. 
The p-value for this correlation was significant (0.027) and the R-squared value 
was positive but less than 50%, indicating that the residuals were highly variable 
from this line. This suggests that there may be a weak association, but as can be 
seen from the figure 5.12 panel A, there are a few data points at the lower end of 
the GD1a inhibition, and therefore there may be excessive variability within the 
data to support this relationship.  
Similarly we looked for a relationship between the amount of inhibition by cholera 
toxin B, and the presence of other serum factors, such as GA1 antibody binding.  
The fitted regression line was almost horizontal, with an R-squared of 0.0%, and 
therefore there was no relationship between the amount of GA1 binding and the 
degree of CTB blocking in the treated cells (Figure 5.12 panel B).   It should be 
noted also, of that the two sera which display the highest degree of CTB blocking 
(around 0.5 fold change); one is GA1 negative, whilst the other is strongly 
positive.   
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Figure 5.12. Relationship between PC12 binding and combinatorial 
microarray binding. Scatterplots are drawn with individual data point 
representing values for individual patient serum from 16 anti-GM1-positive 
MMN patient sera. Panel A plots the neuraminidase-increased binding effect 
(expressed as fold change treated over untreated cells) against the 
percentage of inhibition seen on the microarray lipid complex of GM1:GD1a 
compared to GM1 alone. It was theorised that the greater the inhibitory effect 
of GD1a on binding to GM1, the greater the increase in binding with 
neuraminidase. However, as displayed by the best fit line panel A, there is a 
pattern towards the converse relationship although this relationship may be 
weak. Panel B displays the degree of inhibition of serum binding to cells by 
pre-incubation with cholera toxin B, which was expressed as fold change CTB 
over no CTB groups (both neuraminidase treated). This showed a horizontal 
line fit with no correlation between these two variables.  
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5.4    Discussion 
Three different approaches to the detection of antibody-ligand interaction in MMN 
sera were used in this study. 
First, it was demonstrated that novel solid-phase antibody detection assay, PVDF 
microarray, correlated well with the standard method of antibody detection, 
ELISA, which is used widespread in clinical diagnostic labs for anti-glycolipid 
antibody testing. The major advantage of using the PVDF glycolipid microarray, 
or ‘microarray’, is that using smaller amounts of all materials, larger cohorts of 
samples can be screened against expanded panels of ligands, allowing more 
opportunities to screen for antibody interaction with pairs of glycolipids.  The 
microarray array method may have been more sensitive for detection of antibody 
binding to GM1 single lipid which was not already detected by ELISA, however it 
depends on the value employed for upper limit of normal, and this may have to 
be decided by screening a larger cohort of healthy controls as had been done for 
the GM1 ELISA. Using the microarray, antibody binding to a novel epitope was 
found to be the most specific for MMN, composed of GM1 ganglioside paired with 
galactocerebroside (GalC), a major glycosphingolipid of the myelin sheath in both 
central and peripheral nervous system  (Lisak et al.,1980). From our cohort of 33 
MMN sera tested, all sera were reactive against the GM1:GalC complex, 
including those that were not reactive to either GM1 single or GalC single. This 
finding has great impact upon the understanding to the immunopathogenesis of 
MMN, as patients who were previously considered to be ‘antibody negative’ 
despite having no discerning clinical features from the antibody positive group, 
are now known as also having serological factors which react against glycolipids.  
Thus a more unifying theory of antibody-driven pathogenesis may be plausible in 
this neuropathy.  
In addition, in all MMN sera in this cohort it was demonstrated that GalC pairing 
increases the intensity of antibody binding to GM1, thus we have another 
example of enhancement of glycolipid pairing in a neurological clinical disease 
group.  It is known that GM1 is present mostly on the axonal surface and GalC on 97 
 
the myelin. It could be assumed that GM1:GalC pairing may occur at the 
paranodal loops, where the myelin and the axon juxtaposed. Given that 
conduction block in MMN is thought to occur due to disruption at the nodes of 
Ranvier, it is an attractive idea that GM1:GalC antibodies bind to the paranodal 
loops, fix complement and form MAC pores, leading to conduction block.   
Findings from the microarray reveal that the anti-GM1 antibody in MMN is 
inhibited by GD1a and GT1b,  gangliosides with terminal sialic acid groups, which 
have been proposed to ‘mask’ the GM1 within lipid rafts in the cell membrane, 
thus shielding it from antibody binding.   
It has previously been demonstrated, using mouse and human monoclonal 
antibodies that there are (at least two identified so far) different types anti-GM1 
antibodies, separated by their ability to bind GM1 in the locale of GD1a, and that 
the monoclonal antibody from an MMN patient was of the GD1a-inhibited type, 
such that it could only bind GM1 when GD1a had been removed by sialidase 
treatment  (Greenshields et al.,2009). Results from the microarray clearly show 
that this also holds true for a cohort of MMN sera, that all the anti-GM1 antibodies 
in MMN are complex inhibited by local GD1a in solid phase immunoassays. This 
seemingly is a unifying feature of MMN, and a further clue towards the 
pathogenesis of this condition.   
Furthering the biological relevance of these findings, MMN sera was applied to 
live cell cultures of PC12 cells known to contain mono-, di- and poly-
sialogangliosides. Cholera toxin avidly bound to GM1 on the cells regardless of 
sialidase treatment, thus native GM1 was present in abundance enough that anti-
GM1 recognising factors could bind to untreated cells. Further to that, we 
repeated the experiments using mouse mAbs DG1 and DG2, and human 
monoclonal SM1 from MMN patient to confirm the presence of the two different 
types of anti-GM1 antibodies.  
Using sera from MMN patients, we showed that anti-GM1 antibody negative sera 
did not bind to PC12 cells, regardless of sialidase treatment. However, almost all 
anti-GM1 positive sera displayed the same binding properties as DG1 and SM1: 98 
 
binding did not occur on untreated cells, but with removal of terminal sialic acid 
residues, converting GD1a and GT1b to de novo GM1, IgM in the patient sera 
bound to the cell membranes. This leads on from the findings that GD1a and 
GT1b were inhibitory on the microarray analysis, and allows us to see that this is 
relevant in a biological membrane. 
DG2 was shown to bind to treated cells up to 45 times the background level, its 
binding would be to both native and de novo GM1 since this antibody is shown 
not to be GD1a inhibited. DG1 (and SM1) on the other hand, bound up to around 
20 times the background level, which is roughly the difference between DG2 
binding to treated and untreated cells, and thus these antibodies may be binding 
to the de novo GM1. However we would expect the full binding potential of the 
GD1a inhibited antibodies to be equal to DG2, since they should also be able to 
bind native GM1 with the removal of neighbouring sialic acid residues. This was 
addressed by Greenshields et al, who first blocked the native GM1 with 
unlabelled cholera toxin, then treated with neuraminidase, and demonstrated that 
this reduced the binding potential of DG1, showing that DG1 also binds to native 
GM1, which has been exposed by sialidase treatment {Greenshields, 2009 47 
/id}. It may be that DG1 and SM1 are unable to bind to the de novo GM1, and 
only bind to the unmasked native GM1, however if this was so, then the pre-
blocked then treated cells would have no binding sites available for DG1, yet 
DG1 does bind in this condition.  We must conclude that DG1 and SM1 can bind 
to both native and de novo GM1, but do not bind all the potentially available GM1 
lipids in either group.  There may be other factors which are inhibitory to the 
binding of these antibodies which remain to be discovered, and further expansion 
of the combinatorial arrays to include not just glycolipids, but other cell membrane 
components such as phospholipids, cholesterols and glycoproteins, may further 
elucidate the subtle interactions of neighbouring epitopes on the binding of 
antibodies to glycolipids.  
A shortcoming of the results presented here was that cholera toxin B did not 
effectively block the ability of MMN sera to bind to treated PC12 cells, although 
CTB at this concentration demonstrated full blocking activity of the monoclonal 99 
 
SM1, under identical experimental conditions. This implies that there is another 
factor in the MMN serum that binds to PC12 cells, but only when they have been 
sialidase treated. We know that sialidase treatment converts GD1a and GT1b to 
not only GM1 but also to GA1, and that the anti-GM1 antibody has cross 
reactivity (via the terminal Gal-GalNAc epitope) with GA1 and GD1b.  A potential 
explanation for the lack of CTB blocking could be that sialidase treatment 
unblocks GA1 and MMN patient sera binds to both de novo GM1, exposed GM1, 
and exposed GA1. Since there is no reason to suspect that cholera toxin would 
bind to GA1, then this could explain the high mean fluorescence despite CTB 
pre-incubation. However there are shortcomings of this theory, firstly that we 
would then expect CTB to cause a reduction but not complete blocking of MMN 
sera binding, and this was only demonstrated in roughly one-third of patient sera. 
Secondly, there was no relationship between GA1 binding intensity on the 
microarray and the inhibitory potential of CTB.   Thirdly, the same phenomenon 
should perhaps be expected to occur with the MMN mAb, since this in theory, 
should bind the terminal Gal-GalNAc epitope of GA1, however the mAb binding 
to treated cells was fully blocked by CTB.  Further work in this series of 
experiment could use TLC to separate the lipid components of neuraminidase 
treated cells and determine, using ganglioside standards, the factor to which 
MMN serum is binding.  However, what may be highlighted by this experiment is 
the inefficient nature of working with unpurified human serum, and that further 
work to develop monoclonal cell lines should be continued, to further discover the 
characteristics of MMN antibody binding.   
Regarding the discovery of the anti-glycolipid-complex antibody (anti GM1:GalC) 
as specific for MMN, the next logical step would be to validate this finding in a 
larger cohort of MMN patients.  If this revealed that this epitope was highly 
sensitive and specific for MMN, then new diagnostic tests should be developed 
for accessible testing of this antibody in potential cases of MMN. This would aid 
the diagnostic yield, and reduce the number of cases of MMN with delayed 
diagnosis and delayed treatment due to diagnostic uncertainty. ELISA could 
easily be used for this purpose, with mixing of the gangliosides prior to coating of 100 
 
the wells, and correlation studies between ELISA glycolipid complex binding and 
microarray binding should be carried out to test whether this test can potentially 
be used.  This may herald a more sensitive and specific diagnostic tool for MMN, 
and opens up the potential of screening other autoimmune conditions for complex 
antibodies, both within the nervous system and beyond.  101 
 
6   Conclusion of Thesis 
This project, in its entirety, has made multiple advances in the field of 
autoimmune neuropathy. Firstly, it has been the first human trial of complement 
inhibition in an immune-mediated neurological disease, and should herald the 
beginning of others. It has demonstrated that eculizumab can be given in patients 
with MMN and certainly did not worsen their condition, nor interfere with the 
beneficial effect of IVIg in this condition. There was however, an increase in side 
effects, especially headache. Many of the side effects relate the drug being a 
biological agent. Some of the side effects could potentially be avoided with the 
development of non-biological complement inhibitors, as some of the 
experimental compounds, which demonstrated inhibition of nerve disruption in 
animal models, may soon be developed for use in humans. The risk of 
meningococcal septicaemia would remain even with these non-biological 
compounds however, and therefore therapeutic complement inhibition will never 
be without significant risks. However no patients in this trial had bacterial 
infection. Overall, the safety profile was felt to be acceptable, and certainly all 
patients tolerated the drug.   
In this study, it has been shown that concurrent administration of high dose IVIg 
caused a decrease in the monoclonal antibody concentration, which provides the 
first human evidence of this effect. Despite this, eculizumab retained its 
pharmacological activity, and therefore can be given concurrently with IVIg 
without reduced effect. Within the limitation of the open-label study design, there 
were some indicators of a possible benefit of complement inhibition, which were 
superadded to the IVIg benefit. This sheds some light on the pathogenesis of the 
condition, as although there perhaps some response the complement inhibition, 
the necessity for the other immunomodulatory effects of IVIg remained. It is 
suspected that this has much to do with the chronic nature of this neuropathy, 
and it is most likely that complement inhibition may be more efficacious in the 
prevention of the initial inflammatory injury, as has been demonstrated widely in 
the animal models. This leads to future studies of intervention, in which 
complement inhibitors could be aimed at patients with new or recent diagnoses of 102 
 
MMN. It is suspected that complement inhibition could prevent progression of 
disease. A longer treatment period is necessary, as the small changes in 
neurophysiology could increase with time, even in chronic lesions, with removal 
of complement injury which may allow remyelination and axonal repair, a process 
which is likely to take longer than 14 weeks. However the difficulty with running 
trials in immune-mediated neuropathies, given the rarity of cases and difficulties 
with finding sensitive outcome measures, may hinder trials. In the acute immune-
mediated neuropathy setting, complement inhibition is predicted to be more 
efficacious, and evidence presented here should support this.  
In addition to the clinical trial, the experimental laboratory work presented here 
elucidates further the nature of the antibody-basis to this disease. Firstly, it has 
been the first study to identify an immunological target in patients who have been 
demonstrated so far to be antibody negative. Validation studies in larger cohorts 
of MMN patients are required, and if this epitope is widely associated with MMN, 
then this could potentially open up the field of immunodiagnostics in the testing 
towards antigen-pairs or antigen-complexes.  These theories could be 
extrapolated to many other autoimmune conditions, and contribute to the 
understanding of pathogenesis, diagnostics and therapeutics in many body 
systems.  Further advances are being made within this research group, to 
miniaturise the immunoassays further, allowing screening of large libraries of lipid 
complexes, which in time could be used to analyse the combinative effects of the 
various components of cell membranes, in particular looking at the lipid rafts, and 
their interplay with serological factors in disease. 
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Appendix 1  
Patient Information Sheet (written by Professor H Willison) 
 
 
Version 1, 25/11/08 
 
Patient Information Sheet 
SAFETY AND TOLERABILITY OF ECULIZUMAB IN THE TREATMENT 
OF MULTIFOCAL MOTOR NEUROPATHY: A SINGLE CENTRE OPEN 
LABEL STUDY 
 
We would like to invite you to take part in a research study.  Before you decide 
you need to understand why the research is being done and what it would involve 
for you. Please take time to read the following information carefully. Talk to others 
about the study if you wish. Ask us if there is anything that is not clear or if you 
would like more information.  
 
Part 1 This part provides details on the purpose of this research study 
1. Who is conducting the research? 
The  research  is  being  carried  out  by  Professor  Hugh  Willison  from  the 
Department of Neurology.  
2. What is the purpose of the study? 
The  main  purpose  is  to  see  how  safe  and  how  well  tolerated  the  anti-
inflammatory drug called eculizumab is, when used for treatment of patients with 
multifocal motor neuropathy (MMN).  Eculizumab has never been used to treat 
MMN before. Eculizumab is currently available in the UK for use in patients for a 
different  condition  and  has  been  used  to  treat  approximately  1000  patients 
worldwide  with  a  range  of  different  autoimmune  diseases.  The  secondary 
purpose  of  this  study  is  to  gather  information  on  the  clinical  effectiveness  of 
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eculizumab  in  patients  with  MMN,  and  to  see  whether  being  treated  with 
eculizumab reduces your requirement for intravenous immunoglobulin (IVIg). 
3. Why have I been invited? 
You  have  been  invited  to  take  part  in  this  study  as  you  have  MMN  and  are 
already receiving treatment with IVIg or have responded to IVIg treatment in the 
past. 
4. Do I have to take part? 
No, you do not. It is up to you to decide.  Taking part in this study is entirely 
voluntary.   We  will  describe  the  study  and  go  through  this  information  sheet, 
which we will then give to you.  You will be asked to sign a consent form to show 
you have understood our explanation and have agreed to take part. You are free 
to withdraw from the study at any time, without giving reason. This will not affect 
the standard of care you receive or your future treatment.  
5. What does taking part involve? 
Vaccination 
In order to protect you against infection with meningococcus you will be required 
to  be  vaccinated  against  Neisseria  meningitides  at  least  2  weeks  before  you 
begin  the  study.    Eculizumab  works  by  blocking  the  action  of  proteins  called 
complement.  In the body, the complement system acts to cause inflammation 
and helps the body fight infection.  Neisseria meningitides, is a bacteria which 
causes meningitis and can be contracted in patients whose complement system 
is not working fully. A very small number (less than 1%) of patients receiving 
eculizumab have developed meningitis. We will provide the vaccine for you in our 
clinic  before  you  start  treatment  with  eculizumab.    The  vaccine  is  given  as  a 
single injection.   
You will be given a study card which you should carry with you at all times whilst 
you  are  receiving  treatment  with  eculizumab  and for  3 months  after  your  last 
treatment.    You  should  show  this  card  to  any  doctor  or  other  health  care 105 
 
professional eg. nurse, pharmacist, or dentist that is involved in your treatment.  
The card also lists the signs and symptoms that you should be alert for.  They 
are: 
o  Headache with nausea and/or vomiting 
o  Headache and fever 
o  Headache with a stiff neck or back 
o  Fever of 103° F / 39.4° C or higher 
o  Fever and a rash 
o  Confusion 
o  Severe muscle aches combined with flu-like symptoms 
o  Sensitivity to light 
If  you  experience  any  of  these  symptoms  then  you  should  contact  the  study 
doctor immediately or if you cannot reach the doctor, you must go to the nearest 
Accident and Emergency department and show them the study card.   
Women of childbearing potential 
If you are a woman of childbearing potential then you will be required to have a 
blood test before you start on eculizumab treatment to confirm that you are not 
pregnant.    You  must  use  adequate  contraception  during  treatment  with 
eculizumab and for 5 months after treatment.  This is because it can take several 
months for the body to fully eliminate eculizumab and the effect of eculizumab on 
unborn children is not yet known.  The study doctor will discuss contraception 
with you.   
Treatment and monitoring 
There will be two treatment phases to your involvement, a run in period up to 8 
weeks long, then a 14 week treatment period, followed by an 8 week run out 
period.  In  all  these  periods  you  will  receive  regular  assessments  and 
examinations. 
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You  will  be  given  your  normal  IVIg  treatment  and  asked  to  complete  self-
evaluation questionnaires in the first instance. This will last for a maximum of 8 
weeks and will be followed by a physical examination and some muscle strength 
tests. You will be asked to complete the self evaluation test once a week.  Once 
the study doctor has reviewed the information provided, you will begin treatment 
with the study drug. 
Treatment Period 
Following the run-in period, you will be given the study drug Eculizumab by a drip 
through a tube directly into one of your veins before your IVIg treatment. This 
treatment will last for 14 weeks in total.  You will receive eculizumab infusion as 
follows: 
Week 0, 1, 2 and 3 – one infusion containing 600mg of eculizumab 
Week 4 – one infusion containing 900mg of eculizumab 
Weeks 6, 8, 10 and 12 – one infusion containing 900mg of eculizumab 
Each infusion of eculizumab will take approximately 25 to 45 minutes, but may 
take longer.  Following each infusion you will be monitored for one hour. 
During the treatment period you will continue to receive IVIg if it is required. If 
your motor function does not get worse then you will not be given IVIg during this 
period. 
Prior to, and just after the first infusion periods, a small volume (10mls; equivalent 
to 2 teaspoonfuls) of your blood will be checked for levels of the drug. This will 
require 2 additional blood tests per infusion. 
Run-out Period 
Following the treatment period there will be a period of 8 weeks where you will 
not receive Eculizumab and in which time your IVIg treatment will be put back to 
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6. Expenses and Payments 
You will not be paid for your involvement in this study.  You will be given money 
to cover the costs of your travel. 
7. What will I have to do? 
The trial protocol follows a carefully structured series of visits to hospital in which 
the trial drug and any IVIg you require is administered, and in which a series of 
observational measurements are made on your muscle performance. These will 
be described to you in detail by the trial doctors. You will need to attend hospital 
on a weekly basis for the first 4 weeks to receive your infusion of Eculizumab and 
on  a  fortnightly  basis  for  the  next  10  weeks.  During  some  of  your  visits, 
measurements  of  your  strength  and  performance  on  particular  tasks  will  be 
made. At some visits, blood tests may also be taken. At home, on a weekly basis, 
you  will  complete  a  short  self  evaluation  questionnaire  -  this  will  let  us  know 
whether you require further treatment with IVIg. If you are currently involved in 
another research study please discuss this with one of the study doctors whose 
names are at the back of this sheet.   
You should bring along all medicines that you are currently taking including any 
that  you  have  obtained  without  a  prescription  eg.  herbal  or  over-the-counter 
medicines to each study visit. 
8. What drug is being tested? 
Eculizumab is being tested. It is one of a new class of drugs referred to as 
monoclonal antibodies.  It has not previously been used to treat patients with 
MMN but has been used to treat other diseases.  Many similar drugs are now 
used to treat a wide range of diseases, including inflammation and cancer. The 
drug will be administered by intravenous drip. 
9. What are the possible advantages and disadvantages of taking part in 
this study? 
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It is hoped that treatment with Eculizumab will have a positive effect on the 
symptoms of MMN and that in this study it will reduce the need for IVIg infusions.  
The results of this study will be made public and provide information to both the 
medical and patient communities. Eventually, if this and future studies 
demonstrate that Eculizumab has a positive effect, it may be possible to 
introduce it into routine clinical practice for MMN, although this may take time and 
is not guaranteed. 
Disadvantages 
There is a very small risk of contracting bacterial infections, including a form of 
meningitis. Steps have been taken to reduce this risk further by vaccination, and 
to ensure that any infection is treated promptly.  After receiving the meningitis 
vaccine, the most commonly reported adverse effects were pain and redness at 
the  injection  site.    Most  of  these  were  reported  within  48  hours  following 
vaccination.    Other  common  side  effects  are  headache,  drowsiness,  nausea, 
vomiting and diarrhoea and loss of appetite, but these should not last long.   
It is also possible that you may develop other side effects from treatment with 
Eculizumab  which  may  be  mild,  moderate  or  severe.    Possible  side  effects 
include allergic reactions, which may require additional treatment.  Other known 
side effects, which were very common (occurring in about 1 in 10 patients) that 
have  been  reported  include  headache,  dizziness,  runny  nose  or  sore  throat, 
nausea, diarrhoea, back pain, pain in joints, fever and bruising.  Other common 
side effects include itchy skin, rash, cold sores, infections, and abdominal pain.   
If you notice any side effects that you are concerned about you should discuss 
these with the study doctor.   
There is also an inconvenience factor as you will have to complete forms and 
examinations, and attend hospital more frequently than usual during the course 
of the study. 
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When  the  study  is  finished  you  will  go  back  to  receiving  your  normal  IVIg 
treatment. It is normal practice for drug companies to conduct larger trials before 
making long term recommendations on introduction of a new treatment. However, 
if both the investigators and the patient agree that Eculizumab appears to have 
been  beneficial,  over  and  above  the  benefit  achieved  by  routine  IVIg  therapy 
alone, it may be possible for you to continue on the treatment on a named patient 
basis until further studies on larger groups of patients have been conducted, and 
agreement  to  fund  the  treatment  has  been  received  from  the  NHS.  This 
arrangement will be discussed with you at the end of the study. 
11. What happens to the information? 
Your identity and personal information will be completely confidential and known 
only  to  the  research  team  and  NHS  Greater  Glasgow  and  Clyde  staff  or  UK 
regulatory authority staff who monitor research studies.  The information obtained 
will remain confidential and stored within a locked filing cabinet. The data are 
held in accordance with the Data Protection Act, which means that we keep it 
safely and cannot reveal it to other people, without your permission. 
 
This completes part of the patient information sheet. If the information in 
part 1 has interested you please continue to read the additional information 
in Part 2 before making a decision to participate. 
Part 2, This part provides more information. 
12. What if relevant new information becomes available? 
If we receive new information about the study drug during your participation the 
study  doctor  will  tell  you  about  this  and  discuss  whether  or  not  you  should 
continue. If you want to continue we may ask you to sign an updated consent 
form. If the study is stopped for other reasons we will tell you and arrange your 
continuing care. 
13.What will happen to me if I don’t want to continue with the study? 110 
 
You are allowed to withdraw from this study at any time. Your data will be used 
up to the time you withdraw unless you inform the study doctors that it shouldn’t 
be used. We will destroy all identifiable samples if you wish. 
14. Involvement of your family doctor. 
We will notify your GP of your involvement in this study. 
15. What will happen to the samples I give? 
Your  samples  will  be  analysed  in  the  laboratory  for  routine  clinical  tests,  for 
antibody and complement activity and for anti-nerve antibodies. There will be no 
genetic testing of your samples. 
16. Will my taking part in this study be kept confidential? 
All information relating to your participation in this study will remain confidential 
and be stored in keeping with the Data Protection Act 1998. 
17. What will happen to the results of this study? 
The  study  results  will  be  published  in  a  clinical  neurology  journal  and 
disseminated at neurology meetings. 
 
18. Who is organising and funding this research? 
NHS Greater Glasgow and Clyde and The University of Glasgow are sponsoring 
this study. Alexion Pharmaceuticals is providing funding to support this research. 
21. Who has reviewed the study? 
This  study  has  been  reviewed  by  the  West  Glasgow  (1)  Research  Ethics 
Committee.  
22. If you have any further questions? 111 
 
We will give you a copy of the information sheet and signed consent form to 
keep. If you would like more information about the study and wish to speak to 
someone not closely linked to the study, please contact Dr O’Leary, Consultant 
Neurologist at the Southern General Hospital (Tel: 01412011100).  
23. Contacts: 
Professor  H  Willison,  Dr  J  Overell,  Dr  A  Fitzpatrick  are  contactable  at  the 
Southern General Hospital on 0141 201 2474, 201 2461 and 201 2096. 
24. What if there is a problem? 
In the event that something does go wrong, you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for a legal 
action  for  compensation  against  Glasgow  University  &  Greater  Glasgow  and 
Clyde NHS. You may have to pay your legal costs. 
25. If you have a complaint about any aspect of the study? 
If you are unhappy about any aspect of the study and wish to make a complaint, 
please  contact  the  study  doctors  in  the  first  instance  through  the  Southern 
General  Hospital  (Telephone:  0141  201  2474,  201  2461  and  201  2096).  Any 
complaint  about  the  way  you  have  been  dealt  with  during  the  study  will  be 
addressed.  The normal NHS complaint mechanisms are also available to you 
and details for this can be obtained from the hospital. 
Thank-you for your time and co-operation 
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